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Tho’ much is taken, much abides; and tho’
We are not now that strength which in old days
Moved earth and heaven, that which we are, we are;
One equal temper of heroic hearts,
Made weak by time and fate, but strong in will
To strive, to seek, to find, and not to yield.
Alfred Lord Tennyson
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11 Introduction
1.1 Neurotrophic Factors
A pioneer of neurobiology, Rita Levi-Montalcini,
Figure 1.1 – NGF-induced neu-
ritogenesis. Chicken sensory gan-
glia from eight-day-old chickens
were isolated and cultivated without
(a) and with (b) NGF. With this ex-
periment Levi-Montalcini and Calis-
sano [1979] were able to show the
outgrowth promoting ability of NGF
(Calissano et al. [2010]).
died recently on 30 December 2012. Together with
her colleague Stanley Cohen, she was a recipient of
the Nobel Prize for Physiology or Medicine in 1986
for "their discovery of growth factors", namely the
first neurotrophic factor: nerve growth factor (NGF).
By implanting mouse sarcomas intra- and extra-
embryonically into chicken embryos, she was able
to prove the existence of a neurite outgrowth pro-
moting agent which lead to hyperplasia in the whole
sympathetic system of the embryo (Levi-Montalcini
[1952] Watts [2013]).
A modern definition states "neurotrophic factors
are secreted molecules that play a crucial role in the
development, function, maintenance, and plasticity
of the nervous system" (Alsina et al. [2012]). But
Levi-Montalcini’s results were not fully accepted
until almost twenty years after the discovery, when
NGF was further studied and isolated for the first
time (Bocchini and Angeletti [1969]). Since then,
more members of the same protein family, which
were named neurotrophins, have been identified.
These are the the brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-
3), neurotrophin-4/5 (NT-4/5) and neurotrophin-6 (NT-6, only in fish). NT-4/5 was
first discovered in Xenopus laevis, named NT-4, while a human neurotrophin was
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identified and named NT-5, before it was shown that the factors were homologous
and thus named NT-4/5 (Dawbarn and Allen [2003]). In addition, other proteins
with neurotrophic activity, belonging to different growth factor families, are known
today. Amongst others, these are glial-cell-line-derived neurotrophic factor (GDNF),
transforming growth factor alpha (TGF-α), platelet-derived growth factor (PDGF)
or ciliary neurotrophic factor (CNTF). Today, the list is still growing (Yuen et al.
[1996]).
Levi-Montalcini’s work was a foundation for the neurotrophic theory which hypothe-
sises that after the innervation of the target tissue is completed, neurons compete for
neurotrophic factors, probably by perfecting access to these factors (e.g. via axonal
branching or formation of synapses) and not due to a limited supply of them. Neu-
rons without access to neurotrophic factors undergo apoptosis in order to establish
a quantitative equilibrium between neurons and target tissue (Oppenheim [1989]).
This theory was adapted and further extended: it is now known that trophic factors
are not only provided via secretion by the target cells, but also via autocrine sig-
nalling from the neuron itself and via paracrine signalling from other non-neuronal
cell types. Furthermore, one neuronal population can be supplied not only by one,
but by multiple trophic factors, whereas one trophic factor can supply more than
one population of neurons (Yuen et al. [1996]). Neurons from the central and pe-
ripheral nervous system differ even more in their behaviour towards neurotrophic
factors than subpopulations of neurons. Meyer-Franke et al. [1995] revealed that, in
contrast to cells from the peripheral nervous system (dorsal root ganglia, sensory or
sympathetic neurons), postnatal rat retinal ganglion cells from the central nervous
system do not respond to BDNF treatment alone. Unlike NGF in dorsal root gan-
glia, BDNF will not keep a high percentage of these cells alive for a longer period
of time. But increasing the intracellular cyclic adenosine monophosphate (cAMP)
levels, e.g. by adding forskolin, or stimulating the electrical activity by adding KCl,
greatly promoted the survival effect of the trophic factors. The authors discussed
that cAMP might increase the number of receptors for trophic factors on the cell
surface, which makes the cell more sensitive towards them.
The neurotrophic theory also provides a foundation for the understanding of neu-
ronal death during embryonic brain development. It has been known for many
years that - depending on the specific brain region - between 20% and 80% of the
differentiated neurons undergo apoptosis during neurogenesis (Oppenheim [1991]).
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Brain development is absolutely dependent on programmed cell death of neuronal
precursor cells; this was shown in several knockout mice deficient of regulatory el-
ements of apoptosis. For example, caspase-3- and caspase-9-deficient mice exhibit
a dramatical excess of neurons in the central nervous system, forming highly disor-
ganised structures (Kuida et al. [1996], Kuida et al. [1998]). The limited amount
of neurotrophins protects selected cells, while others undergo apoptosis (de la Rosa
and de Pablo [2000]). That ensures that the density of the surviving cells matches
the needs of the target tissue.
However, not only during brain development, but also in the adult nervous system,
neurotrophic factors play an important role in mediating neuronal viability, differ-
entiation and morphology (Reichardt [2006]).
1.2 Receptors and Signalling Pathways
1.2.1 The Tropomyosine-related Kinase Receptor Family
The family members of the neurotrophins are small proteins of about 30 kDa that are
produced as protein precursors (pro-neurotrophins). These are posttranslationally
modified by proteolysis to their mature form, which has a molecular weight of ap-
proximately 13 kDa. The mature proteins form homodimers that are non-covalently
linked and are secreted by the cell (Dawbarn and Allen [2003], Reichardt [2006]).
These dimers are able to activate designated receptors to induce positive signalling
pathways as well as negative feedback loops which restrict their own signal trans-
duction.
Each member of the neurotrophin family has one main receptor from the tropomyosine-
related kinase (trk) receptor family. Some neurotrophins, e.g. NT-3, are also able
to activate more than one receptor, but the binding to their main receptor is more
stringent.
The trk family of receptors consists of three main members (trkA, trkB and trkC)
and their splice forms. Their structure shows common features: they consist of an
extracellular factor binding domain which is specific to the respective neurotrophin
and has an immunglobuline-like structure. Intracellularly, they have a tyrosine ki-
nase domain. When a factor is bound, the receptor dimerises and the cytosolic
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domains transphosphorylate each other. Different signalling cascades are now acti-
vated, the major ones being:
• Ras leads to the activation of the mitogen-activated kinase pathway (MAPK)
and ultimately to a differentiation-promoting pathway, neurite outgrowth and
transcription of anti-apoptotic proteins
• Phosphatidyl inositol-3 (PI3) kinase phosphorylates phosphoinosides, which
mediate an activation of the kinase Akt. Via downward cascades, Akt induces
neuronal outgrowth and survival, e.g. by blocking proteins from the pro-
apoptotic Bcl-2 family. Furthermore, the 3-phosphoinosides recruits proteins
of the Rho-GTPases to the membrane, e.g. Cdc42, Rac and Rho. Their main
task is the organisation of the actin-based cytoskeleton and thus to promote
neurite outgrowth along neurotrophic gradients
• Phospholipase Cγ1 promotes synapse plasticity by activating protein kinase
C-regulated pathways which, amongst others, lead to a release of Ca2+ and an
activation of Ca2+-dependent kinases.
Other signalling pathways are involved as well, though they are not fully understood
yet. It may be possible that different groups of neurons also use different signalling
cascades (Crowder and Freeman [1998], Reichardt [2006]).
1.2.2 The p75NTR Receptor
P75NTR (p75 neurotrophin receptor) was the first receptor discovered to bind NGF.
It was named after its size, 75 kDa, belongs to the tumor necrosis factor superfamily,
and has an intracytosolic death domain. Although it is able to bind all members of
the neurotrophin receptor family, it was shown to bind the pro-neurotrophins with
thousandfold higher affinity (Friedman [2010]).
Figure 1.2 summarises the different binding patterns of neurotrophins with their re-
spective receptors. While the immature pro-neurotrophins bind strongly to p75NTR,
the binding of their mature proteins to the receptor is characterised by a low bind-
ing affinity. Each neurotrophin has a designated receptor, e.g. trkA is the main
receptor of NGF, trkC the main receptor of NT-3, and trkB is shared by BDNF
and NT-4. NT-3 is also able to activate trkA and trkB with lower affinity. The
1 Introduction 5
pro-neurotrophins are not able to bind trk receptors.
Sortilin is a co-receptor for p75NTR and necessary for its activation. When a pro-
neurotrophin is bound, the following pathways are induced (Reichardt [2006]):
• A jun kinase signalling cascade leads to downstream activation of c-jun, the
pro-apoptotic factor p53 and an activation of the fas receptor. All these events
induce apoptosis
• The Nfκb pathway is activated and thus promotes neuronal survival
• Without neurotrophin binding, p75NTR activates RhoA, a small Rho-GTPase,
which further leads to the induction of neuronal outgrowth. When a pro-
neurotrophin is bound, this activation is blocked and outgrowth is inhibited.
This is supported by diminished neuronal outgrowth, shown in a mouse model
with a mutation in the p75NTF gene. While the inactivation of Rho, on the
other hand, increased neuronal outgrowth in primary neuronal cell cultures
(Yamashita et al. [1999]).
Figure 1.2 –Neurotrophins and their re-
ceptors. Different binding patterns of neu-
rotrophin family members with their respec-
tive receptors (figure from Reichardt [2006]).
An overview of the described signalling cas-
cades is also depicted in figure 1.3. De-
pending on which receptor is activated,
several pathways are induced, leading to
the expression of pro- or anti-apoptotic
genes.
In a nutshell, neurotrophic factors are able
to induce different cell signalling pathways,
leading to either survival or death of the
cell. The outcome depends on the binding
factor (pro-neurotrophin or neurotrophin)
and on the receptor (trk or p75NTR). An
equilibrium of a neurotrophic factor and its
immature protein is thus necessary in the
cell to maintain its status quo. That is the
reason why antibody-mediated depletion of
NGF in cell culture may actually result in
better survival of the cells (D. Sanes, A.
Thomas [2006]).
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Figure 1.3 – Signalling pathways of neurotrophic factors. Overview of the signalling
pathways that can be induced by the binding of neurotrophic factors to their respective re-
ceptors. Both receptors, trk and p75NTR are able to bind a factor and activate a downstream
cascade. Trk receptors activate downstream events, as MAP kinase pathway and induction of
Akt, which induce the expression of anti-apoptotic factors. p75NTR can induce the expression
of pro-apoptotic factors (c-jun) as well anti-apoptotic factors (Nfκb), dependent on regulatory
mechanisms, which are further described in the next chapter (figure from Reichardt [2006]).
1.3 Regulation
The neurotrophic receptors p75NTR and tropomyosine-related kinase (trk) trigger
completely opposing cellular pathways, which decide between life or death of a neu-
ron. The cellular events leading to this decision are not fully understood yet, but
different mechanisms for the regulations of signal cascades have been described.
The amount and the concentration of a neurotrophin (expression level) is one reg-
ulatory mechanism for the cell. Additionally, the expression levels of the receptors
decide their frequency on the cellular surface. The more receptors are available for
activation, the lower is the amount of neurotrophins needed for the same outcome.
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Only a few molecules are necessary for the activation and once the downward cas-
cade is started, it amplifies itself. Furthermore, negative feedback loops are activated
after the signalling cascade starts, which allows for their own regulation (Yuen et al.
[1996]).
Therefore, expression of neurotrophins and their respective receptors is the first
method of regulation. Additionally, many external factors, such as cytokines, steroids
and TGFβ are able to influence the expression levels of neurotrophins, too (Re-
ichardt [2006]).
Posttranslational modifications allow for further regulation. An important step is
the endoproteolytic processing of the pro-neurotrophins into their mature form,
which can be controlled by the expression levels of proteases and is thus probably
tissue-dependent. Neurotrophins can be cleaved by several proteases, intracellularly
as well as extracellularly (Lee et al. [2001]). Different factors are cleaved and se-
creted within the same cell type. In hippocampal neurons, NGF is cleaved in the
trans-Golgi network, and secreted via the constitutive pathway, so that it is always
available to the cell. In the same cell type, BDNF is not cleaved in the trans-Golgi
network, but packed from there into secretory granules and secreted via the reg-
ulated secretory pathway. Proteolytic processing takes place within the granules,
which are released upon specific signalling (Farhadi et al. [2000]).
Surprisingly, both neurotrophic receptor types (trk or p75NTR) are located in the
same multiprotein complexes on the surface of the cell and even influence each other.
This mechanism allows the activation of one receptor type, while at the same time
suppressing the other. Reichardt [2006] describes three proteins and complexes that
have been shown to interact with both receptors simultaneously, namely the ankyrin
repeat-rich membrane spanning adaptor protein (ARMS), caveolin and the complex
p62-Traf6-IRAK. When trk is bound by a factor, ARMS is phosphorylated and in-
duces prolonged activation of Ras and Erk (figure 1.3), supporting the trk-activated
downstream events. Caveolin and p62-Traf6-IRAK also allow for the interaction
of trk and p75NTR and possibly suppress pro-apoptotic signalling to support trk-
mediated anti-apoptotic signalling.
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1.4 Influence of Neurotrophic Factors on the
Cytoskeleton
The cytoskeleton is a structural scaffold that supports the stability of eukaryotic
cells. Besides stabilisation, it allows the cell to move, is a scaffold for cell organelles
and allows transport within the cell. It consists of three different filaments: mi-
crofilaments (actin), intermediate filaments and microtubules. They differ by their
composition, size, associated proteins and functions (Fletcher and Mullins [2010]).
Each microtubule consists of 13 protofilaments, linear heterodimeric structures of
aligned α- and β-tubulin. Microtubules are the most complex of the filaments and
are characterised by a phenomenon called "dynamic instability", a sequence of rapid
growth and subsequent destabilisation, which are termed "rescue" and "catastro-
phe", respectively. This phenomenon is a quick response mechanism to changes in
the environment (Conde and Cáceres [2009]).
Many associated proteins help to stabilise or destabilise microtubules, mediate move-
ment (motor proteins), or to sever them. Neurons are highly polarised cells; the
subcellular localisation of their microtubule-stabilising proteins is also clearly po-
larised. E.g. map2 is a stabilising factor in dendrites, but not in axons. Tau on the
other hand, is a microtubule-stabilising protein only in axons (Conde and Cáceres
[2009]).
The polarity of the neuron is established early in development. The cells start with
the outgrowth of several neurites with the same characteristics, before one of the
neurites turns into an axon, while the others become dendrites. They differ in their
polarisation of microtubules: in axons they are organised with the plus end towards
the outer end of the cell, whereas the orientation in dendrites is mixed. The axon
is the signal-transmitting end of the cell while dendrites are the receiving ends. For
further outgrowth, the axon develops a growth cone, a structure with filopodia that
reaches towards the target (D. Sanes, A. Thomas [2006]).
On the tip of the growth cone, tyrosinated tubulin is concentrated. In contrast to
its acetylated form, it is dynamic and has a half-life of only about five minutes.
Acetylated tubulin on the other hand, is stable and has a half-life of about thirty
minutes. The dynamic tubulin allows fast reactions to the environment (compare
figure 1.4).
Neurotrophic factors induce neuronal outgrowth by influencing the cytoskeleton of
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Figure 1.4 – Cytoskeletal characteristics of a neuronal growth cone. Microtubules
(MT) and actin interact to form a structure which gets more stable towards the cell body, but
is able to react to changes in the environment quickly at the tip of the growth cone. Three
different regions can be identified: the peripheral (P)-domain (comprised of actin filaments),
the central (C)-domain (stable microtubules) and the transition (T) domain (Lowery and Van
Vactor [2009]).
the target cell. To elucidate this process, double knockout mice of NGF and Bax
are a suitable model (Markus et al. [2002]). Bax is a pro-apoptotic member of the
Bcl-2 family. When Bax is missing, apoptosis is reduced, thus, the neuronal death
induced by the NGF-deficiency is diminished. This allows to study the influence
of NGF on neuronal outgrowth in vivo. In this mouse model, neurons from dor-
sal root ganglia survived without NGF and sent neurites out into the spinal cord.
Surprisingly, only peripheral cutaneous axons were missing at the time of birth. It
can be concluded from these results that only axonal outgrowth over long distances
is NGF-dependent. Other factors might serve as intermediate targets over short
distances (Markus et al. [2002]).
A theory on how NGF induction of neuronal outgrowth works, was published by
Zhou et al. [2004] (figure 1.5). As was described earlier, NGF activates phosphatidylinositol-
3 (PI-3) kinase at the growth cone. This leads to the downstream activation of the
small GTPases Cdc42, Rac and Rho, which organise the actin-based cytoskeleton.
The activation of PI-3 kinase furthermore leads to the activation of integrin-linked
kinase (ILK) and thus to the inactivation of glycogen synthase kinase 3 β (GSK-3β).
This kinase phosphorylates adenomatous polyposis coli (APC). When APC is not
phosphorylated, it binds microtubules, stabilises them and thus induces microtubule
polymerisation. Together with actin polymerisation this leads to the outgrowth of
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the axon.
Figure 1.5 – Induction of neuronal outgrowth by NGF. NGF induces neuronal out-
growth by activation of actin polymerisation and microtubule assembly at the same time by
activation of phosphatidylinositol-3 kinase. Figure from Zhou et al. [2004].
Cytoskeletal deficits go hand in hand with many neurodegenerative diseases, for
example Alzheimer’s disease (AD), Parkinson’s disease (PD) or the motor neuron
disease amyotrophic lateral sklerosis. Defective transport of proteins along the axon
leads to an accumulation of cytoskeletal structures in these diseases (McMurray
[2000], Brandt [2001]).
1.5 Neurodegenerative Diseases
Neurodegeneration is a hallmark of many diseases, defined by a structural loss of
neurons in the central nervous system leading to cognitive deficits of various kinds.
Well known examples include Alzheimer’s disease, Parkinson’s disease, Huntington
disease, Pick’s disease, Prion diseases, and others. Most of these diseases exhibit an
aggregation of misfolded proteins resulting in amyloid plaques. Amyloids are defined
as insoluble aggregations of proteins that are soluble under normal physiological
conditions. These aggregations appear filamentous, as for example the so-called tau-
tangles, misfolded tau that aggregates intracellularly and is a feature of Alzheimer’s
disease. Several different proteins are prone to form amyloid plaques by misfolding,
and even though they share no structural similarity, the principal characteristics of
their aggregations resemble each other.
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Figure 1.6 – Model for the formation of amyloid plaques. This figure presents a
model for the formation of fibrils that form amyloid plaques. These plaques are a hallmark
of neurodegenerative diseases and can arise from several different soluble proteins. The boxes
describe several steps, e.g. the misfolding itself or the oligomerisation that could be used as
therapeutic targets (figure from Skovronsky et al. [2006]).
Neurodegenerative diseases can be characterised by the protein forming the amy-
loid plaques and the localisation of these plaques within the brain. It is not clear
though, whether these aggregates themselves or their precursors, namely oligomeres
and protofibrils, are the cause or a side-effect of neurodegeneration. Nevertheless,
they present us with therapeutic opportunities and potential targets. As described
by Skovronsky et al. [2006], it is indicated that the amyloid plaques correlate and
may be linked with incorrect axonal transport, inhibition of protein degradation
and apoptosis. Figure 1.6 illustrates the process of fibril aggregation from the na-
tive protein, through the misfolded protein, to oligomers and complete fibrils. It
also presents potential targets for drug design, as for example the upregulation of
the protein degradation machinery as well as the inhibition of fibril formation, and
others (Skovronsky et al. [2006]).
1.5.1 Neurotrophic Factors in Neurodegenerative Diseases
Neurotrophic factors were shown to be survival-promoting on a number of degen-
erating neurons in neurodegenerative diseases. Some examples are described in the
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following, where an imbalance of neurotrophic factors is either a causing agent or a
consequence in the development of the disease. Moreover, studies were performed
with a focus on neurotrophic factors as a therapeutic option.
Alzheimer’s disease (AD) is characterised by a loss of cholinergic neurons in the basal
forebrain, cerebral cortex, and the hippocampus, leading to a defective cholinergic
function and thus arousing dementia and cognitive deficits.
Different hypotheses regarding the reason for this cell loss exist (Hardy and Selkoe
[2002], Dawbarn and Allen [2003]) . The amyloid hypothesis states that the plaques
itself are the causing agents. In contrast, the tau hypothesis makes hyperphospho-
rylated tau accountable for the development of Alzheimer’s disease. Alzheimer’s
disease belongs to the group of tauopathies due to its intracellular accumulation of
hyperphosphorylated tau, in so-called tau-tangles or neurofibrillary tangles. Tau is a
microtubule-associated protein that binds and stabilises microtubules. The tangles
form inside the cell, thus disturbing the microtubule cytoskeleton integrity and the
transport mechanism of the neuron (Skovronsky et al. [2006]).
The cholinergic hypothesis regards a decreased production of acetylcholine as a
main reason for Alzheimer’s disease. The loss of cholinergic neurons leads to re-
duced cholinergic activity, even though the overall cognitive deficits are actually
worse than the loss of neurons alone accounts for (Dawbarn and Allen [2003]).
It could be presumed that neurotrophic factors are reduced in Alzheimer’s disease
and thus neurons degenerate, but this is not the case. On the contrary, despite no
reduction of mature NGF, there is a two-fold increase of immature pro-NGF in the
parietal cortex of brains affected by Alzheimer’s disease (Fahnestock et al. [2001]).
An imbalance of mature NGF and its precursor protein might lead to neuronal death
by activation of p75NTF, possibly due to a dysfunction of NGF retrograde transport.
Additionally, knockout mouse models of NGF or its receptor trkA show a decrease
in cholinergic activity and a loss of cholinergic neurons in the hippocampus, cortex
and the basal forebrain (Dawbarn and Allen [2003]). Cooper et al. [2001] showed in
a mouse model of Down syndrome (due to the extra copy of the amyloid precursor
protein - APP - gene, patients with Down syndrome do develop Alzheimers disease
as well) that retrograde transport of NGF is diminished and that NGF in the basal
forebrain is thus decreased, as it is the case in AD patients. Additionally, it was
possible to rescue cholinergic neurons of the basal forebrain in vitro and in vivo by
supplementing NGF to the medium or via intracerebroventricular injections, respec-
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tively. In rat models of the disease, intracerebroventricular injections were shown to
enhance cognitive deficits (Dawbarn and Allen [2003]).
Intracerebroventricular injections of NGF in a clinical trial with three patients did
partially confirm results from animal models. Cognitive deficits were improving, but
a severe side-effect reported by all patients, was pain, which stopped after the injec-
tions. It was discussed that the pain was due to a hyperplasia of p75NTF positive,
trkA negative Schwann cells at the medulla and the spinal cord, which was found
to be nonmalignant and reversible in rat models (Dawbarn and Allen [2003]).
Nonetheless, other forms of treatment with NGF are under examination, including
the injection of retrovirally infected fibroblasts, overexpressing NGF, or the nasal
administration of NGF. Both show histological improvements in the basal forebrain
of rats and rhesus monkeys (Dawbarn and Allen [2003]).
Another example for a neurotrophic disease in which an imbalance of neurotrophic
factors occurs is Parkinson’s disease (PD). It is characterised by a loss of dopamin-
ergic neurons within the substantia nigra, a structure in the ventral midbrain, for
unknown reasons. A consequence of this is the reduced production of the neurotrans-
mitter dopamine which leads to an imbalance of neurotransmitters, neuronal loss and
the common symptoms of PD (tremor, rigidity, slower movement, and postural insta-
bility). Until now, treatment is confined to symptomatic approaches and the attempt
to treat the loss of dopamine with its precursor form L-3,4-dihydroxyphenylalanine,
or L-dopa. L-dopa is able to cross the blood-brain barrier and increases the dopamine
levels, but does not protect neurons from degeneration (Gill et al. [2003]).
Histologically, inclusions can be detected in moribund neurons, the so-called Lewy
bodies. They consist of accumulated α-synuclein and ubiquitin. That associates
Parkinson’s disease with the group of synucleopathies. The amount and localisation
of Lewy bodies varies from patient to patient and is a hallmark of the spontaneous
form of PD (Dawbarn and Allen [2003]).
Glial-derived neurotrophic factor (GDNF) plays an important role in the develop-
ment of dopaminergic neurons and offers the potential ability to protect motor neu-
rons and dopaminergic neurons, as was shown in animal models of the disease. Ax-
onal outgrowth and improved motor functions were detected after intracerebroven-
tricular injection or the direct injection of GDNF into the substantia nigra (Gill
et al. [2003]). In contrast to the results in animal models, intracerebroventricular
injections into human patients of PD did not lead to an improvement of the disease.
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It was hypothesised that the increased amount of tissue did not allow GDNF to
penetrate into the correct regions of the brain and thus other means of delivery had
to be found (Gill et al. [2003]).
A clinical trial study phase 1 with five patients and without a control group therefore
injected GDNF directly into the putamen for the period of one year. The putamen
is the area in the brain with the most drastic reduction of dopamine in PD patients.
Gill et al. [2003] were able to show via positron emission tomography (PET) scan
that the dopamine storage increased in these patients and their score of disease de-
creased significantly with only little side effects.
These are two examples for neurodegenerative diseases where neurotrophic factors
are involved. The question whether these factors are a cause of the disease (and if
they are, if this is the sole cause) or a by-product of neuronal loss, is not solved yet.
But interestingly, rodent models of the diseases can at least be partially rescued
with the administration of neurotrophic factors. Further research on known and yet
unknown neurotrophic factors is necessary to enhance our fundamental knowledge
and might thus offer the possibility to improve neurodegenerative diseases.
1.6 Hepatoma-Derived Growth Factor-Related
Protein-3 (HRP-3)
Hepatoma-derived growth factor-related protein-3, in short HRP-3, is a 23 kDa sized
protein with mitogenic activity that was first cloned by Ikegame et al. [1999] in a
screening of expressed sequence tag (EST) databases.
It is one of five proteins established as family members of the name-giving Hep-
atoma-derived growth factor (HDGF), which was discovered in the supernatant of
HuH-7 cells (Nakamura et al. [1994]). The other family members are: HDGF-related
proteins 1, 2 and 4, and the lens epithelial-derived growth factor (LEDGF). They
all share a N-terminal homologous domain (homologous to the amino terminus of
HDGF, in short: HATH), while they are differing in their C-termini. Human HRP-3
and HDGF share an identity of 81.4% in their HATH domain, while their non-HATH
regions differ completely.
A common feature of HDGF family members is the bipartite nuclear localisation
signal (NLS), which is localised in the conserved HATH region and the non-HATH
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region and allows HRP-3 to translocate to the nucleus, as shown in the immunfluo-
rescence in figure 1.7.
Although HDGF is currently the best
Figure 1.7 – Immuncytochemistry of pri-
mary cortical neurons. β-III-tubulin stains a
neuron-specific tubulin isoform and thus indicates
the outward appearance of the cell (in blue). The
green staining is derived by an HRP-3-specific an-
tibody and detects a strong nuclear signal which
is common for postmitotic neurons.
described protein of the family, its func-
tion is still unknown. It has mitogenic
effects on fibroblasts, hepatocytes, en-
dothelial cells and others (Everett et al.
[2000], Nakamura et al. [1994], Oliver
and Al-Awqati [1998]) and is presumed
to play a role in angiogenesis, organo-
genesis and cancer development. It can
be used as a prognostic marker for vari-
ous cancer types and many publications
show ample evidence that HDGF ex-
pression in tumours is correlated with
a bad prognosis for patients, as in hep-
atocellular carcinoma (Hu et al. [2003]),
non-small cell lung cancer (Iwasaki et al.
[2005]), gliomas (Hsu et al. [2011]), breast cancer (Chen et al. [2012]) and others.
Even though HDGF is overexpressed in melanomas (Bernard et al. [2003]), no for-
mation of melanomas was detected in a transgenic mouse model by Sedlmaier et al.
[2011]. In this study, transgenic mice, overexpressing HDGF in melanocytes and
with a heterozygous deficiency of the tumour suppressor gene Ink4a, were exposed
neonatally to UV light. Mice did not develop melanomas, thus, it was concluded
that HDGF does not have oncogenic activity itself, but is a factor for non-oncogenic
addiction. This concept describes the need of a cancerous cell for certain factors to
keep its malignancy (Weinstein [2002]).
Whereas an overexpression of HRP-3 in mantle cell lymphomas has already been
described before (Miller et al. [2000]), a more recent publication indicates a rela-
tionship between HRP-3 and tumorigenesis that is similar to HDGF. It was not
only shown that HRP-3 is necessary for anchorage-independent growth in liver car-
cinomas but also that knockdown via siRNA in hepatocyte carcinoma cells greatly
reduced the resistance against chemotherapeutics (Xiao et al. [2012]).
HDGF is strongly expressed in many organs, as for example the brain, heart, lung,
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liver, spleen and muscle. In contrast, the literature differs as far as the expression
of HRP-3 is concerned. Ikegame et al. [1999] display human HRP-3 mRNA via
Northern blot analysis in the heart, brain, testis and kidney, Xiao et al. [2012] addi-
tionally show very weak signals for the lung, liver and pancreas, also via Northern
blot analysis.
On the other hand, Abouzied et al. [2004], describe a restricted protein expression of
mouse HRP-3 in the brain via immunoblotting, more specifically its neurons, with
only small amount of protein in testis. Whether HRP-3 shows different expressions
in humans and mice, or whether the level of expression in other organs beside the
brain are too weak to detect in immunoblotting, remains to be elucidated.
1.7 Neurotrophic Activity of HRP-3
Despite the differences in the literature regarding its expression, HRP-3 is strongly
expressed in neurons, but not in non-neuronal cells (except to a very small amount
in oligodendrocytes). It is highly regulated during embryonic brain development and
shows varying expression levels at different stages of development. The expression
increases from embryonic day 15 to a very strong expression around birth, decreases
strongly afterwards and is again very high in the adult mouse brain (Abouzied et al.
[2004]).
Additionally, the subcellular localisation of HRP-3 changes during brain develop-
ment and in cell culture. In a primary culture of cortical neurons from E14.5 mouse
brains, a strong signal in neurites (axons and dendrites) is detectable in immunocyto-
chemistry. After 10 days in culture, a translocation into the nucleus is taking place.
In mature neurons, HRP-3 exhibits a strong nuclear expression with no protein de-
tectable extranuclearly (El-Tahir et al. [2009]). The reason for the translocation is
not known, although Xiao et al. [2012] discuss that MAP/Erk signalling might play
a role. They transfected human hepatocyte carcinoma cells with myc-HRP-3 and
report a translocation from the nucleus into the cytoplasma after stimulation with
EGF.
HRP-3 is secreted by cells, although it lacks a classic signal peptide. It might thus
be secreted via non-classical secretory pathways. A study on HDGF has shown that
the first ten amino acids of HDGF act as a secretion signal that is also able to release
a reporter gene (eGFP and SNAP) into the supernatant (Thakar et al. [2010]). The
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phosphorylation of Serin 165 is inevitable for this secretion mechanism in HDGF.
The conservation of the HATH domain suggests that HRP-3 is secreted similarly to
HDGF.
HRP-3 has neurotrophic activity when offered as an extracellular supplement, as
shown by Abouzied et al. [2010]. It promoted neurite outgrowth in a cell culture
of primary cortical neurons and was able to keep the cells alive as sole supplement
in the culture medium. The effects of 100 ng/ml HRP-3 resembled similar trophic
effects as 5% fetal calf serum (FCS) in the medium. An antibody-mediated inhi-
bition of HRP-3 diminished this effect. Furthermore, coating of cell culture plates
with HRP-3 recombinant protein, led to an enhanced neuronal outgrowth compared
with HDGF or β-galactosidase as a control. This effect was comparable to laminin
as an extracellular matrix.
HRP-3 is interacting with microtubules, promoting their stability and thus lead-
ing to neurite outgrowth. It was shown in vitro and in vivo via transfection of a
cytoplasmically-located NLS mutant of HRP-3 that the amount of acetylated tubu-
lin increases. That is a sign for the stabilisation of microtubules. HRP-3-mediated
neurite outgrowth and inhibition of this outgrowth after knockdown of HRP-3 is
manifested by its ability to promote microtubule polymerisation (El-Tahir et al.
[2009]).
The neurotrophic and neurite-outgrowth promoting ability of HRP-3 is an effect
that is performed by extracellular HRP-3 (via secretion or the addition of recom-
binant protein in cell culture). This is in contrast to the intracellular effects on
the cytoskeleton, more specifically the stabilisation of microtubules. The uptake of
HRP-3 by the cell has not been proven yet, nor is it known how an extracellular
administration of HRP-3 would modulate the cytoskeleton.
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1.8 Expectations and Objectives
Hepatoma-derived growth factor-related protein-3 (HRP-3) is a secreted neurotrophic
factor that is most dominantly expressed in neurons. It has the ability to stabilise
microtubules and thus is able to promote neurite outgrowth. Furthermore, as a sole
medium supplement, it can keep neurons alive and is highly regulated during brain
development. Not only the amount of expressed protein, but also the intracellular
localisation, changes during development. Regardless of this, the precise function of
HRP-3 is still unknown and demands further elucidation.
Via manipulation of embryonic stem cells, an HRP-3-deficient mouse line will be cre-
ated using a targeting vector for homologous recombination. Exon II of the Hrp-3
gene will be targeted and replaced with the genomic information for enhanced green
fluorescent protein (eGFP) as a reporter gene that is driven under the endogenous
promoter. Further features of the targeting vector include a hypoxanthine phos-
phoribosyltransferase (HPRT) cassette for positive selection and a diphteria toxin
fragment A cassette for negative selection reducing the number of cells which have
not undergone a homologous recombination event.
The introduction of a reporter gene will give further insights into the expression of
HRP-3 and will help to answer the question whether HRP-3 expression in mice is
restricted to brain and testis.
Knockdown of HRP-3 in primary cortical neurons leads to a reduced neurite length.
The same cultures prepared from HRP-3-deficient mice will give further insight on
HRP-3-related neuritogenesis.
A loss of function of HRP-3 might result in a drastic phenotype, because of its
strongly regulated expression in brain development. As a result, embryonic lethality
might be expected, as well as neurodegenerative phenotypes.
Other congenital defects can be expected, as well. Wat et al. [2010] identified mi-
crodeletions of the chromosomal region 15q25.2, where - amongst others - HRP-3
is located. These microdeletions are associated with a higher risk for congenital
diaphragmatic hernia and the authors state that the loss of HRP-3 might lead to
the patient’s cognitive deficits.
Hence, the aim of this thesis is to describe the generation of an HRP-3-deficient
mouse model to investigate HRP-3 expression more closely and establish a prereq-
uisite for future functional analysis.
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2 Materials
2.1 Chemicals
Unless stated otherwise, chemicals were obtained from Merck, Sigma Aldrich, Roth
and Fluka. Restriction enzymes were bought from Fermentas. [α32P ]-dCTP was
acquired from Hartmann Analytic. All chemicals specific for embryonic stem (ES)
cell cultures are described in table 2.4.
2.2 Kits
Ready-to-use kits that were used in this work are described in the following table.
Table 2.1 – Kits
Name Manufacturer Cat. no.
DC Protein Assay BioRad # 500-0111
ECL Western Blotting Substrate Pierce # 32106
Prime-it II Random Primer Labelling Kit Stratagene # 300385
QIAGEN Plasmid Mini Kit Qiagen # 12123
QIAGEN Plasmid Midi Kit Qiagen # 12143
QIAGEN EndoFree Plasmid Maxi Kit Qiagen # 12362
QIAquick Gel Extraction Kit Qiagen # 28704
QuantiTect Reverse Transcription Kit Qiagen # 205311
SuperSignal West Pico Chemiluminescent Sub-
strate
Pierce # 34080
Super Sensitive Link-Label IHC Detection Sys-
tem
BioGenex # QP900-L
Vectastain ABC Kit Vectastain
Laboratories
# PK-4000
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2.3 Plastic Ware and Consumables
If not stated otherwise, all general consumables were obtained from Sarstedt, Fal-
con and Greiner. Sterile plastic ware for cell culture was bought from Falcon and
Sarstedt. Consumables that do not fit in these categories are listed in the following
table.
Table 2.2 – Consumables
Name Manufacturer Cat. no.
Blotting paper Albet-Hahnemuehle # BP005 5860
Cryogenic vials Nalgene # V5007-500EA
Electroporation cuvettes, 4mm
gap
Molecular Bio Products # 5540
Fuji Medical X-Ray film Fuji # 47410 08389
Hybond-XL blotting membrane GE-Healthcare # RPN2020S
Illustra MicroSpin G-50 Columns GE-Healthcare # 27-5330-01
Microscope cover glasses, 24 x
60mm
Labomedic # LAME110071
Microscope slides Engelbrecht # 11101
Protran Nitrocellulose Hybridiza-
tion Transfer Membrane
Schleicher & Schuell # NBA083C001EA
Sterile filters 0,2 µm, 0,1 µm Millipore # 83.1826
SuperFrost Plus microscope slides Thermo Scientific # 4951PLUS
2.4 Lab Equipment
Non-standard lab equipment is described in the following table.
Table 2.3 – Lab Equipment
Name Manufacturer
Agarose gel electrophoresis chambers Peqlab
Bacterial incubator Heraeus
Binocular SMZ1500 Nikon
Cooling centrifuge Z233 MK Hermle
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Table 2.3 – Lab Equipment
Name Manufacturer
Cooling centrifuge F34-6-38 Eppendorf
Electrophoresis chamber Mini Protean 3 Bio-Rad
Electroporator Gene pulser 2 Bio-Rad
Film developer Agfa Curix C60 Agfa Health Care
Fluorescence microscope Zeiss Axiovert 100M Carl Zeiss
Fujifilm FLA5100 Fluorescent Image Analyser Fuji
Incubator CO2 Water Jacketed Incubator Forma Scientific
Microtom RM 2155 Leica
Microplate reader Tecan
Microwave Vacuum Histoprocessor RHS-1 Milestone
Nanodrop 2000 Peqlab
Odyssey Infrared Imager Li-Cor
PCR Cycler T3 Thermocycler Biometra
Phosphoimager BAS-1800II Fujifilm
Power supply PAC 200 Bio-Rad
Power supply PAC 300 Bio-Rad
Semi-dry Western Blot Peqlab
Scintillation counter Beckmann LS-6500 Beckmann
Sonication bath Branic Branson
Table centrifuge 54 15 D Eppendorf
Tissue-Tek VIP Sakura
Tissue-Tek TEC Sakura
Ultraturrax T25 Janke & Kunkel
UV-Transilluminator BioDoc Analyze Biometra
Water bath for paraffin slides HI 2110 Leica
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2.5 Chemicals and Supplements for ES Cell
Culture
Chemicals and cell culture media, as well as supplements for embryonic stem cells are
listed in the following table. All supplements are either autoclaved or filter-sterilised
if not bought sterile.
Table 2.4 – ES Cell Culture
Name Manufacturer Cat. no.
Cell culture grade water Gibco # 15230
B27 supplement Gibco # 0080085SA
Bovine serum albumin (BSA) Sigma Aldrich # A9318
Dimethyl sulfoxide (DMSO) Hybri-Max Sigma Aldrich # D2650
Fetal calf serum (FCS, embryonic stem cell
qualified)
PromoCell # C-37387
Gelatin from porcine skin Sigma Aldrich # G2500
Glasgow-MEM, BHK-21 Gibco # 21710-082
GlutaMAX Gibco # 35050038
HAT-supplement Sigma Aldrich # H0262
L-Glutamine 200mM solution Gibco # 25030081
Lif in-house produc-
tion
ß-Mercaptoethanol Sigma Aldrich # M3148
Monothioglycerol Sigma Aldrich # M6145
Neurobasal medium (NBM) Gibco # 21103049
Sodium pyruvate Gibco # S8636
Non essential amino acids Gibco # M7145
Phosphate buffered saline (PBS) 1 x Gibco # 14190
Penicillin-Streptomycin (Pen/Strep), 100 x Gibco # 10378016
Trypsin Gibco # 15090046
Trypsin inhibitor Gibco # R-007-100
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2.6 Chemicals and Polymerases
Non-standard chemicals, as well as polymerases are listed in the following table.
Table 2.5 – Chemicals and Solutions
Name Manufacturer Cat. no.
Colchicine Sigma Aldrich # C9754
3,3’-Diaminobenzidine tetrahydrochlo-
ride hydrate (DAB)
Sigma Aldrich # D5637
Dimethyl sulfoxide (DMSO) Sigma Aldrich # D2650
LongAmp Taq DNA Polymerase New England
Biolabs
# M0323S
Phenol-Chloroform isoamyl alcohol Roth # A156.3
Mitomycin C Sigma Aldrich # M4287
REDtaq ReadyMix Sigma Aldrich # R2523
TRIzol Reagent Invitrogen # 15596-026
2.7 Buffers and Solutions
The buffers and solutions that were used in this thesis are described in the following
table. All buffers were prepared with double distilled water (ddH2O) and stored at
room temperature if not stated otherwise.
Table 2.6 – Buffers and Solutions
Name Constituents Production
Ampicillin stock
solution
100mg/ml Storage at -20 ◦C,
final concentration
100 µg/ml
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Table 2.6 – Buffers and Solutions
Name Constituents Production
Blotting buffer
(Western blot)
48 mM Tris pH 9.2
39 mM Glycine
20% Methanol (v/v)
0.038% SDS (w/v)
Church hybridisation
buffer
0.25 M NaPi (500ml 10x NaPi,
see below)
7% SDS (w/v)
1 mM EDTA
Ad 1 l H2O
Church washing
buffer
0.02 M NaPi (80ml 10x NaPi, see
below)
1% SDS (w/v)
Ad 2 l H2O
DAPI
5mg/ml Treat in ultrasonic
bath to solve. Fi-
nal concentration:
1:25,000
Denaturation solution
0.5 M NaOH (20 g/l)
1.5 M NaCl (87.7 g/l)
Depurination solution 0.25 M HCl (19ml/l)
DNA loading buffer
6x
10 mM Tris-HCl (pH 7.6)
0.03% Bromophenol blue
0.03% Xylene cyanol FF
60% Glycerol
60 mM EDTA
Ethidiumbromide
solution
5mg/ml 3 µl per 100ml agarose
gel
2 x HBS
280 mM NaCl pH 7.13
50 mM HEPES
1.5 mM Na3PO4
Kanamycin stock
solution
50mg/ml Storage at -20 ◦C,
final concentration
100 µg/ml
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Table 2.6 – Buffers and Solutions
Name Constituents Production
Lysis buffer (proteins)
100 mM Tris-HCl pH 7.4
150 mM NaCl
1 mM EDTA
1 mM MgCl2
1% Triton X-100
1 µg/ml Leupeptin
1 µg/ml Pepstatin
10 µg/ml Phosphatase inhibitors
2.5 mM DTT
Laird lysis buffer
100 mM Tris/HCl pH 8.0 Add Proteinase K
5 mM EDTA immediately before
0.2 M NaCl use
0.5% SDS (w/v)
300 µg/ml Proteinase K
LB medium
10 g Bacto tryptone
5 g Bacto yeast extract
10 g NaCl
Solve in 1 l H2O, ad-
just to pH 7.5 with
NaOH, autoclave
LB plates
1.5% Agar (w/v) in LB medium Autoclave; after cool-
ing down to 50 ◦C,
pour into plates
Mowiol
Solution 1:
20mg Mowiol 4-88 (Calbiochem)
80ml PBS (pH 7.3)
40ml Glycerol (87%)
2 mM NaN3
Solution 2:
2.5mg n-Propylgallate
50ml PBS (pH 7.3)
50ml Glycerol
Working solution:
7.5ml solution 1
+ 2.5ml solution 2
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Table 2.6 – Buffers and Solutions
Name Constituents Production
NaPi 10 x (0.5 M)
0.5 M Na2HPO4x2H2O (89 g)
3-4ml H3PO4
Adjust to pH 7.2 with
H3PO4
Phosphate buffered
saline (PBS) 10x
1.36 M NaCl Ad 1 l H2O
53 mM KCl pH adjusted to 6.75
202 mM Na2HPO4x2H2O
19 mM KH2PO4
Paraformaldehyde
8% (PFA)
40 g Paraformaldehyd
325 µl 1 M NaOH
ad 450ml H20
Heat PFA / H20 /
NaOH to dissolve.
Adjust pH to 8.0,
then add 10 x PBS.
50ml 10 x PBS
Saline-sodium citrate
buffer (SSC) 20x
175.3 g NaCl
88.2 g Sodium citrate
pH adjusted to 7.0, 1 l
H2O.
SDS-gel running
buffer 10x
30.3 g Tris base Ad 1 l H2O
144 g Glycerol
10 g SDS
Separating gel buffer 1.5 M Tris-HCl pH 8.8
Stacking gel buffer 0.5 M Tris/HCl pH 6.8
SSPE 20x
3.6 M NaCl (174 g/l H2O)
0.2 M Na2HPO4 (27.6 g/l H2O)
0.02 M EDTA (7.4 g/l H2O)
pH 7.7, ad 1 l H2O
Tris-acetate-EDTA
(TAE) 50x
2 M Tris (242.28 g)
7.85 mM EDTA (37.2 g)
57.1ml Glacial acetic acid
Adjust to pH 8.3, ad
1 l H2O
Tris-buffered saline
(TBS) 10x
100 mM Tris-base (12.11 g)
1.5 M NaCl (87.6 g)
Adjust pH to 6.95, ad
1 l H2O
TBS/Tween
1 x TBS
0.5% Tween 20 (v/v)
Transfer buffer
(Southern Blot)
0.4 N NaOH (16 g/l H2O)
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2.8 Eukaryotic Cell Cultures
2.8.1 Buffers and Solutions for Eukaryotic Cell Cultures
If not bought sterile, all buffers and solutions for ES cell cultures were either auto-
claved or filter-sterilised. They were stored at 4 ◦C, if not stated otherwise.
Table 2.7 – Buffers and Solutions for Cell Cultures
Name Constituents Production
Complete neurobasal
medium (NBM)
50ml neurobasal medium
2% B27
1 mM GlutaMAX
1x Pen/Strep
Freezing medium for
ES cells
50% Culture medium for ES cells
30% FCS
20% DMSO
2x Stock solution,
store at -20 ◦C
Freezing medium for
mouse embryonic
fibroblasts (MEF)
60% Culture medium for MEFs
20% FCS
20% DMSO
2x Stock solution,
store at -20 ◦C
Gelatine (for coating) 1% Gelatine in H2O (w/v) Autoclave two times
Growth medium
DMEM with GlutaMAX
5% FCS
1 x Pen/Strep
Growth medium
for ES cells
Glasgow-MEM, BHK-21
15% FCS
1 mM Sodium pyruvate
2 mM L-Glutamine
1% Non essential amino acids
0.1% Leukemia inhibitory factor
0.15 mM Monothioglycerol
Growth medium
for mouse
embryonic
fibroblasts
(MEF)
DMEM
10% FCS
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Table 2.7 – Buffers and Solutions for Cell Cultures
Name Constituents Production
1 mM β-Mercaptoethanol
2 mM L-Glutamine
1 x Pen/Strep
Hepes-buffered-
saline (HBS) for
electroporation
10x
10 g HEPES
16 g NaCl
0.25 g Na2HPO4x2H2O
0.74 g KCl
2 g D-Glucose
Adjust to pH 7.2,
ad 200ml H2O. Filter
sterilise with a 0.1 µm
filter, store at -20 ◦C
Selection medium
Cell culture medium for ES cells
add one vial HAT-Supplement
ES-Trypsin
400ml PBS (1x)
100ml EDTA (1.85 g/l)
5ml 2.5% Trypsin
Store at -20 ◦C
Table 2.8 – Plasmids
Number Name Description
- pLif For the production of lif (Smith et al. [1988]),
kindly provided by Dr. C.Völker.
- Exon2KO-HSV Generated by Rainer Gallitzendoerfer (unpub-
lished).
- pDTA Kindly provided by Joachim Degen.
P9 pcDNA3.1 Expression vector (Invitrogen). Contains the Cy-
tomegalovirus enhancer-promoter.
P11 pHWloxP Cloning vector, contains a floxed HPRT-Minigene
(Magin et al. [1992]).
P18 pBluescript (pBSK) Cloning vector (Stratagene).
607 HRP3-Exon2KO6.1 HRP-3 targeting vector, cloned in this work.
610 Probe2 Probe for HRP-3 Southern blots, cloned in this
work.
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2.9 DNA Ladders
Table 2.9 – DNA Ladders
Name Company Fragments [bp]
λ/HindIII Fermentas (# SM0102) 23,130, 9416, 6557, 4361,
2322, 2027, 564
λ DNA EcoRI + HindIII Fermentas (# SM0192) 21,226, 5148, 4973, 4286,
3530, 2027, 1904, 1584,
1375, 947, 831, 564
50 bp ladder Fermentas (# SM0371) 1000, 900, 800, 700, 600,
500, 400, 300, 250, 200, 150,
100, 50
1 kb plus ladder Fermentas (# SM1334) 10,000, 8000, 6000, 5000,
4000, 3000, 2000, 1500,
1000, 500
2.10 Bacterial Strains
Table 2.10 – Bacterial Strains
Name Genotype
XL-1 Blue supE44 hsdR17 recA1 endA1 gyrA46 thi relA1lac F’[proAB+, laclq, lacZ∆M15, Tn10 (tetr)]
JM-110
rpsL (Strr) thr leu thi-1 lacY galK galT ara tonA
tsx dam dcm supE44 ∆ (lac− proAB)
[F, traD36, proAB, lacIqZ∆M15]
2.11 Eukaryotic Cell Lines
All cell lines were regularly tested for mycoplasma.
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Table 2.11 – Cell Lines
Name Origin Notes
HM-1
mouse embryonic stem cells from
120/ola mice
Magin et al. [1992], HPRT-
deficient. Cell line was a gift from
Dr. Joachim Degen
COS-7
monkey Production of leukemia inhibitory
factor (lif) for ES cells
MEF
mouse embryonic fibroblasts Isolated from NMRI mice, de-
scribed in 3.3.1
2.12 Primers
Table 2.14 describes the primers that were used in this thesis to either generate
constructs or genotype mice.
2.13 Plasmids
Table 2.8 contains plasmids that were used either for the cloning of the targeting
construct or other purposes. Maps of all plasmids are listed in the supplemental
materials.
2.14 Antibodies
Primary and secondary antibodies that were used in this thesis are described in
table 2.12 and 2.13.
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Table 2.12 – Antibodies
Name Origin Company WB ICC IHC AR
alpha-tubulin mouse DSHB (clone 12G10) 1:10,000 - - -
beta-III-tubulin mouse Dianova (T-1315) 1:1500 1:100 1:100 10mM Sodium
citrate, pH 6
GFP mouse hybridoma supernatant from
Prof. Magin
1:1000 1:100 - -
GFP mouse Roche - - 1:500 10mM Sodium
citrate, pH 6
GFP rabbit Abcam (# ab6556) 1:5000 1:500 - -
C-terminal ms HRP-3 rabbit Abouzied et al. [2004] 1:1000 1:100 1:100 2mM EDTA
HDGF rabbit Abouzied et al. [2004] 1:1000 1:100 - -
Human HRP-3 mouse Santa Cruz, clone A10 (# sc-
376558)
1:1000 1:100 1:100 2mM EDTA
Table 2.13 – Secondary antibodies
Origin coupled Company WB ICC IHC
goat α mouse alexa 568 Molecular Probes (# A-11061) - 1:600 1:600
goat α rabbit alexa 488 Molecular Probes (# A-11008) - 1:600 1:600
goat α rabbit Cy-2 Dianova (# 111-225-003) - 1:600 1:600
goat α mouse Cy-2 Dianova (# 111-225-164) - 1:600 1:600
goat α rabbit Cy-3 Dianova (# 111-165-144) - 1:600 1:600
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goat α mouse peroxidase Dianova (# 115-035-044) 1:5000 - -
goat α rabbit peroxidase Dianova (# 115-035-003) 1:5000 - -
goat α rabbit biotinylated Jackson Laboratories (# 111-065-144) - 1:600 1:600
Table 2.14 – Primer
Number Name Sequence Usage
1181 BNP 500 AGCCTACCCTCTGGTAGATTG Genotyping of mice, knockout
1482 GFPsense GACAACCACTACCTGAGCAC Genotyping of mice, knockout
1588 HRP-3exon2sense CTATGCCTACGTCTGTTCCTGTT Genotyping of mice, wild type
2004 HRP3Ex4SondeAS TCTCCCCTCTCCTTTTCCAT Sequencing
2476 Eef-2 sense ATCCTCACCGACATCACCAAG RT-PCR
2477 Eef-2 antisense CTGCTCTGGACACTGGATCTC RT-PCR
2742 HRP3-KO-
HPRT-as
CACAGAGGGCCACAATG Sequencing
2841 HDGFqPCRs GACCTGGTGTTTGCGAAGAT RT-PCR
2842 HDGFqPCRas GCTTGCCAAACTTCTCCTTG RT-PCR
2857 HRP-3 sense GCAATGACACGAGAAACACGAC RT-PCR
2858 HRP-3 antisense GACAACAAAGACCGTTGGTTCA RT-PCR
SF04 HRP3ex2kosense ATCGATGTTAATCATAGCAGGGCAGGCAT Cloning of the long homologous arm of
HRP-3-exon2-KO6.1
SF05 HRP3ex2koanti ATCGATGGATGTTGAGGAAGGTTAACCTGAG Cloning of the long homologous arm of
HRP-3-exon2-KO6.1
2
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Table 2.14 – Primer
Number Name Sequence Usage
SF18 HRP3Ex2KOas CTATGCCTACGTCTGTTCCTGTT Genotyping of mice, wild type
SF42 Southern2s AAAAGTCCTCCACAGTCAATCC Genotyping, Southern blot probe
SF70 HRP3KOscras GCTGAACTTGTGGCCGTT Genotyping
SF194 eGFPs CAGCCACAACGTCTATATCATG RT-PCR
SF195 eGFPas GAACTCCAGCAGGACCATG RT-PCR
pEGFP-C2-RP GATCACATGGTCCTGCTG Sequencing
EGFP-N CCGTCCAGCTCGACCAG Sequencing
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2.15 Software
Determination of neurite lengths was performed with the ImageJ plugin NeuronJ
(Meijering et al. [2004]). Clone Manager Version 9 from Sci-Ed was used to generate
plasmid maps and plan constructs. This thesis was written in Texmaker 3.5. Im-
age processing was performed with the Axiovert software (Zeiss), the GNU Image
Manipulation Program (GIMP) 2.8.4 and Inkscape 0.48.
2.16 Trademarks
All names, trademarks, and images are copyright their respective owners.
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3 Methods
3.1 Techniques for the Isolation and
Quantification of Nucleic Acids
3.1.1 Isolation of Plasmid DNA
Isolation of plasmid DNA was performed using the principle of alkaline lysis (Birn-
boim and Doly [1979]). This method allows the separation and isolation of plasmid
DNA from bacterial chromosomal DNA due to different behaviour to denaturing
agents.
For small volumes up to 2ml of bacterial cultures, a mini preparation was performed
using the Qiagen Plasmid Mini Kit according to the manufacturer’s protocol. For
medium cultures up to 50ml a midi preparation was performed using the Qiagen
Plasmid Midi Kit. For the purification of DNA suitable to transfect embryonic stem
cells, the Qiagen EndoFree Plasmid Maxi Kit was used.
3.1.2 Isolation of Genomic DNA from ES Cell Clones
For fast genotyping of ES cell clones, DNA from 96-well plates was isolated. After
aspiration of the growth medium, cells were washed once with 200 µl pre-warmed
PBS. Afterwards, cells were incubated overnight with 50 µl Laird buffer containing
80 µg/ml proteinase K. Plate were placed in a plastic box padded with wet tissues
and incubated at 55 ◦C. The following day, plates were allowed to cool down to
room temperature for one hour, before gently adding 100 µl of 100% ethanol per
well. After one hour of incubation, the plates were then quickly inverted on tissue
paper to dump the ethanol without disturbing the DNA at the bottom of the plates.
The DNA was washed three times with 100 µl 70% ethanol, each time dumping the
ethanol as described. The plates were left to dry at room temperature for one hour,
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before the DNA was solved in 80 µl water, transferred to a microcentrifuge tube and
used for PCR analysis.
3.1.3 Isolation of Genomic DNA from Mouse Tail Biopsies
Genomic DNA for genotyping was extracted from mouse tail biopsies. About 0.2mm
of tail were cut and 500 µl Laird buffer containing 300 µg/ml Proteinase K were
added. The tails were incubated overnight in a shaking water bath at 55 ◦C. The
following day, a phenol-chloroform extraction was carried out (described in 3.1.4).
3.1.4 Phenol-Chloroform Extraction
Phenol-chloroform extraction was carried out to extract genomic DNA for PCR
genotyping or Southern blotting. 1/2 volume phenol-chloroform isoamyl alcohol
was added to the lysate and shaken vigorously. After five minutes of centrifugation
at 15,000 x g, the upper phase, which contains the nucleic acids, was transferred to
a fresh microcentrifuge tube. Following this, one volume of chloroform was added.
The mixture was shaken again, and centrifuged as described. The upper phase was
transferred to a fresh tube. The DNA was precipitated by adding one volume of
isopropyl alcohol. This was shaken and then centrifuged for 10 minutes at 18,000 x g.
The supernatant was discarded, and 300 µl 70% ethanol were used to wash the DNA
pellet. After another centrifugation step, the supernatant was discarded and the
pellet left to dry. 50 - 200 µl of water were used to dissolve the DNA which was then
used for PCR or Southern blot analysis.
3.1.5 Sodium Acetate Precipitation
Sodium acetate was used for the precipitation of small amounts of DNA. The fol-
lowing was added to the solution: 1/10th of sodium acetate (pH 4.6) and an amount
of 100% ethanol equal to 2.5 times the volume of the original solution. After 10
minutes of incubation on ice, the solution was subsequently centrifuged and the su-
pernatant discarded. The DNA pellet was washed once with 250 µl 70% ethanol,
dried, and dissolved in an appropriate amount of water.
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3.1.6 Isolation of Total RNA from Mouse Tissues
TRIzol reagent was used for the isolation of total RNA from mouse tissues. TRIzol
is a monophasic solution of phenol and guanidine isothiocyanate that allows the dis-
ruption of cells and tissues while protecting RNA from degradation through RNases
(Chomczynski and Sacchi [1987]).
1ml of TRIzol per 100mg of tissue was used for the homogenisation in a glass-Teflon
tissue grinder. Homogenates were centrifuged for ten minutes at 12,000 x g, 4 ◦C and
the clear supernatant was transferred to a new 15ml reaction tube. Homogenates
were incubated for five minutes at room temperature to allow dissociation of nucleo-
protein complexes. Subsequently, 0.1ml of 1-bromo-3-chloropropane (BCP) per ml
TRIzol were added. After 15 seconds of shaking and incubation for three minutes
at room temperature, the mixture was centrifuged for 15 minutes at 12,000 x g and
4 ◦C. The clear, colourless upper phase contains the RNA and was transferred into
a fresh tube. 500 µl of isopropanol per ml TRIzol were used to precipitate RNA for
ten minutes at room temperature. After centrifugation for ten minutes at 12,000 x g,
a RNA pellet was visible. After washing with 1ml 70% ethanol per ml TRIzol, and
centrifugation at 7,500 x g for five minutes at 4 ◦C, the RNA was left to dry for ten
minutes. The pellet was then dissolved in an appropriate amount of RNase-free
water by incubating at 55 ◦C for ten minutes.
3.1.7 Estimation of Nucleic Acid Concentration
A Thermo Scientific NanoDrop 2000 spectrophotometer was used to measure nucleic
acid concentration. 50 µg/ml double-stranded DNA, or 40 µg/ml RNA respectively,
have an extinction of 1 at 260 nm. Proteins have their maximum extinction at
280 nm, thus the quotient E260/280 provides indications about the purity of the
nucleic acid. For DNA, the quotient should lie between 1.8 and 2.0. For RNA,
between 1.9 and 2.2, whereas lower values indicate contamination with proteins or
phenol.
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3.1.8 Separation of Nucleic Acids by Agarose Gel
Electrophoresis
To visually estimate DNA concentration, separation by agarose gel electrophoresis
was performed. Agarose forms a polymer and due to their negative charge, nu-
cleic acids migrate through the agarose, depending on their size and conformation.
Different concentrations of agarose were used for different sizes of DNA: 1% for
sizes between 1 and 10 kb and 2% gels for smaller fragments between 0.2 and 1 kb.
Ethidium bromide was used to visualise the DNA. 6 x loading dye was added to the
samples (see 2.6). A voltage of 3 - 4V/cm2 was used for nucleic acid electrophoresis.
3.2 Modification of Nucleic Acids
3.2.1 Restriction Digests
Restriction enzymes from Fermentas were used for digestion of DNA according to
the manufacturer’s instructions. For cloning experiments, 1-3 µg DNA were digested
in a volume of 20 µl for varying time spans ranging from one hour up to twelve hours
at 37 ◦C.
3.2.2 Extraction of Linearised DNA from Agarose Gel
To isolate the requested fragment after a restriction digest, the desired band was
cut from the gel with the help of an UV hand lamp. DNA was extracted using the
QIAquick Gel Extraction Kit (Qiagen) according to the manufacturer’s instructions.
DNA was eluted in 30 µl ultrapure water and the concentration estimated via agarose
gel electrophoresis, see 3.1.8.
3.2.3 Dephosphorylation of Linearised Vectors
To keep linearised vectors from religating, the FastAP thermosensitive alkaline phos-
phatase from Fermentas was used according to the manufacturer’s instructions.
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3.2.4 T4 Polymerase
For the integration of unphosphorylated PCR products in dephosporylated vectors,
the insert had to be phosphorylated first. The T4 Polynucleotid Kinase (T4 PNK)
from Fermentas was used according to the manufacturer’s instructions.
3.2.5 Ligation
To link vector and insert covalently, T4 DNA Ligase (Fermentas) was used. It uses
ATP to form the phosphodiester bond for blunt or cohesive ends respectively. The
molar proportion of vector-to-insert is 1:5. 20 ng vector were incubated with the
appropriate amount of insert for one hour at room temperature, this was followed
by heat shock transformation.
3.2.6 Heat Shock Transformation
Competent XL-1 blue were stored at -80◦C in 90 µl aliquots. For heat shock trans-
formation, the bacterial solution was placed on ice for 5-10 minutes. 10 µl of the
ligation mixture or 10 ng of purified plasmid DNA (re-transformation) were added
to the bacteria (a maximum of 1/10th of the bacterial solution). After a 20 minute
incubation on ice, the heat shock was performed for one minute at 42 ◦C. Bacteria
were left for two minutes on ice to cool down, before 900 µl of LB-medium were
added. The suspension was placed in a shaking incubator for one hour at 37 ◦C,
before plating on the appropriate LB-plates.
3.3 Embryonic Cell Culture
HM-1 cells are an embryonic stem cell line derived from 129/ola mice (Magin et al.
[1992]). They are deficient for hypoxanthine phosphoribosyltransferase (HPRT),
which allows using the HRPT-minigene as a positive selection cassette.
The HM-1 cells were a gift from Dr. Joachim Degen. Those were cultivated in a
Thermo Forma Incubator at 5% CO2 and 37 ◦C. All work was performed using the
sterile bench HERA Safe (Thermo Scientific).
HM-1 cells were cultivated in lif-containing medium (see 2.7, production of lif see
3.3.2) on a layer of mitotic inactive mouse embryonic fibroblasts (MEF or "feeder
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cells", see 3.3.1).
Cell culture flasks were coated with gelatine, using a 0.1% working solution (see
table 2.6). The bottom of the plate was completely covered, and the solution incu-
bated for ten minutes at room temperature, before aspirating.
For thawing of cells, cryo vials were taken from liquid nitrogen, unfreezed in a 37 ◦C
waterbath and quickly transferred into a 15ml reaction tube containing 10ml of
culture medium. Cells were pelleted by centrifuging five minutes at 800 x g and the
supernatant was aspirated. After resuspending in culture medium, cells were then
transferred to the gelatine coated culture dish.
For the feeder cell layer, MEFs were added in a density of 5 x 104 cells per cm2.
They were allowed to settle down for 30 minutes up to one day, before adding the
ES cells to the same flask.
Culture medium was changed daily and embryonic stem cells were subcultured in a
1:3 to 1:6 ratio every two to three days. For subculturing, medium was aspirated
and cells were washed twice with 5ml warm PBS per T25 plate before trypsin was
added (1ml per T25 flask). Dishes were placed in the incubator for 1-5 minutes
until cells formed a single cell suspension. This process was accelerated by careful
tapping on the side of the dish every few minutes. After all cells were detached,
they were resuspended in fresh culture medium and placed on fresh gelatine-coated
dishes. For each subculture, the passage number was increased by one.
To freeze cells, a culture in their logarithmic growth phase was trypsinised as de-
scribed above. Cells were collected in 10ml of medium and pelleted by centrifu-
gation. The pellet was resuspended in 500 µl culture medium and distributed into
cryo vials. Each vial contained about 5 x 106 to 8 x 106 cells. 500 µl freezing medium
(2.7) were added dropwise. Vials were closed and quickly transferred into a Nalgene
freezing container which was then stored at -80 ◦C. After 24 to 48 hours, the vials
were transferred to liquid nitrogen.
3.3.1 Culture of Mouse Embryonic Fibroblasts (MEF)
Isolation
Embryonic fibroblasts were used as "feeder" cells for embryonic stem cells. They
produce and secrete growth factors which help to keep the cells in an undifferentiated
state. HM-1 cells are able to grow MEF-independent, but especially when the cell
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number was low (e.g. for selection) working with the addition of MEFs was preferred
due to the healthier state of the HM-1 cultures.
For the isolation of MEFs, a 13.5 days pregnant C56Bl/6N mouse, was anaesthetised
with chloroform and euthanised by cervical dislocation. The uterus containing the
embryos was taken out and placed into a dish with sterile PBS. All extraembryonic
tissues were removed and the heads cut off. The embryos were dissected using a
scalpel and everything except the liver was transferred into a 15ml reaction tube.
1ml trypsin per embryo was added and incubated for ten minutes in a shaking
waterbath at 37 ◦C. Using a syringe, the suspension was pressed through a 18 gauge
needle until completely homogenised. Cells were taken up in feeder cell medium (see
table 2.7) and plated on two T75 plates per embryo. MEFs were subcultured up to
a maximum of four passages at a ratio of 1:3 every two or three days.
Inactivation and Cryopreservation
For mitotic inactivation 10 µg/ml mitomycin C were added to the confluent culture.
Cells were incubated for three hours at 37 ◦C, before they were washed five times
with warm PBS. MEFs were subsequently trypsinised with 2ml per T75 flask, taken
up in 10ml and pelleted by centrifuging for five minutes at 800 x g. Three vials
of cells were frozen from a T75 plate. Cell pellets were taken up in MEF freezing
medium (see table 2.7) and distributed to the appropriate amount of cryo vials.
Vials were placed in a Nalgene freezing container at -80 ◦C and transferred to liquid
nitrogen two days later.
3.3.2 Production of Leukemia Inhibitory Factor (lif)
Leukemia inhibitory factor (lif) is a growth factor which keeps embryonic stem cells
in an undifferentiated state. Cos-7 cells were used for lif production.
Cells were expanded in ES cell medium without lif, β-mercaptoethanol and antibi-
otics until 15 T75 plates were confluent. Three plates at a time were washed with
PBS twice, trypsinised and taken up in 10ml medium. Cells were centrifuged for
five minutes at 800 x g. The supernatant was discarded and the cell pellet was taken
up in 1.6ml 1 x HBS electroporation buffer (see table 2.6). 800 µl cell suspension
were electroporated with 120 µg pLif at 0.8V and 3 µF. This was repeated once.
Cells were taken up in fresh culture medium and plated on a 15 cm dish.
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After 24 hours, the culture medium was replaced. 25ml fresh medium were added,
left on the plates for 72 hours and harvested. An additional 25ml were added and
left on the cells for 42 hours before harvesting. Both batches were combined, and
filtered first through a 0.45 µm sterile filter, and then through a 0.1 µm filter.
The lif-containing medium was aliquoted and tested for its effectivity. For this, two
24-well plates were plated with ES cells without lif and feeder cells, one with 1,000
cells per well, and one with 500. The freshly produced lif was added in different
concentrations ranging from 1:100 to 1:5,000. As a control, one well is grown with-
out any lif and one with the previously produced batch. Cells were cultivated for
seven days with daily medium replacement and then rated for their differentiation.
The optimal concentration of lif leads to less than 5% differentiated cells.
3.3.3 Gene Targeting of Embryonic Stem Cells
Transfection of ES cells via Electroporation
HRP-3Exon2KO6.1 was used as a targeting vector for the stable transfection of
HM-1 cells. DNA was prepared using the QIAGEN EndoFree Plasmid Midi Kit,
quantified, and 250 µg were digested overnight using PmeI in a total volume of
200 µl. 1 µl was separated using agarose gel electrophoresis to assess the quality of
the digestion. If the plasmid was successfully linearised, a phenol-chloroform extrac-
tion (see 3.1.4) was performed, following a subsequent sodium acetate precipitation
(see 3.1.5). The DNA pellet was taken up in 100 µl sterile cell culture grade water.
A healthy culture of HM-1 in logarithmic growth phase on a T75 plate was used
for the targeting experiment. Cells were trypsinised as described above, taken up,
and pelleted by centrifuging for five minutes at 800 x g. Supernatant was discarded
and the pellet was washed in 10ml warm PBS and centrifuged again. After as-
piration of the supernatant, the cell pellet was resuspended in 800 µl 1 x HBS for
electroporation and DNA was added. After pipetting up and down for two times,
the cell-DNA-suspension was transferred without air bubbles to the electroporation
cuvette. Electroporation was performed immediately using the Gene Pulser 2 (Bio-
rad) at 3 µF and 0.8V. The cuvette was left in place for ten minutes, before cells
were placed in 50ml prewarmed ES cell culture medium and plated on fifteen 10 cm
dishes.
3 Methods 43
Selection of ES Cells and Cultivation of Clones
Aminopterin leads to the blockage of de novo DNA synthesis by inhibiting the
dihydrofolate reductase. Adding hypoxanthine and thymidine gives the cell the pos-
sibility to utilise the salvage pathway, if the hypoxanthine phosphoribosyltransferase
(HPRT) is available. Since HM-1 cells are HPRT-deficient, only cells which have
successfully taken up the targeting vector, are able to survive the selection.
Selection was started 24 hours after electroporation by adding HAT-supplement to
the culture medium (see 2.7). The medium was renewed every 48 hours, every 24
hours after cells started dying. On days 8-12 of the selection, cell clones were picked
with a 200 µl pipette tip under a microscope, and transferred into a 96-well plate on
feeder cells.
Medium in the 96-well plates was renewed daily. After two to six days, the medium
turned yellow within one day, indicating that the cells were crowded enough to be
subcultured. Therefore the medium was aspirated and cells were washed twice with
200 µl prewarmed PBS using a multichannel pipette. 50 µl trypsin were added to
each well and the plates were incubated for five to ten minutes at 37 ◦C until all cells
were detached. 150 µl culture medium were added and cells were resuspended using
the multichannel pipette. Cells were then subcultured on four fresh 96-well plates;
two were used for DNA extraction (see 3.1.2) and two for freezing.
Freezing and Thawing of 96-Well Plates
Freezing of 96-well plates allows easy storage of a high number of ES cell clones. An
indicator for the cells being crowded enough is when the medium of most wells turns
yellow within 24 hours. At this point the medium was then aspirated, cells were
washed twice with 200 µl prewarmed PBS, and 50 µl trypsin were added per well.
Cells were left in the incubator for five to ten minutes with occasional tapping of
the side of the plate, until they were completely detached. 50 µl of freezing medium
were added and cells were resuspended using the multichannel pipette. Plates were
wrapped with Parafilm, placed in a few layers of paper towel and surrounded with
aluminium foil. They were stored at -80 ◦C.
For thawing, plates were placed in the incubator for 24 hours until the cells were
adherent again. Only then was the culture medium renewed. Positive clones and
those surrounding them were then subcultured as soon as possible on 48-well plates.
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Genotyping of ES Cell Clones
DNA from 96-well plates was isolated as described in section 3.1.2. 5 µl of DNA
solution were used for the genotyping PCR. The expected PCR product has a size
of 2,368 bp.
Table 3.1 – Genotyping PCR for ES Cell Clones
(a) Reaction Mix
Amount Components
2 µl Primer SF42 (5 pmol)
2 µl Primer SF70 (5 pmol)
3.75 µl 2 mM dNTPs
5 µl 5 x PCR buffer
1 µl DNA
0.5 µl longAmp Polymerase
ad 25 µl H2O
(b) PCR Program
Step Temp. Time
1 94 ◦C 180 sec
2 94 ◦C 30 sec
3 58 ◦C 45 sec
4 65 ◦C 140 sec to step 2, 34 cycles
5 65 ◦C 600 sec
6 4 ◦C ∞
Karyotype Analysis
To exclude chromosomal aberrations, the number of chromosomes had to be deter-
mined. Mice have a set of 40 acrocentric chromosomes.
Medium on a confluent 6 cm dish was replaced by colchicine-containing medium in
a concentration of 0.1mg/ml. Colchicine stabilises microtubules and therefore pre-
vents the successful completion of mitosis. After one hour of incubation at 37 ◦C,
cells were harvested with trypsin, taken up in 1ml of culture medium and centrifuged
for five minutes at 500 x g. The supernatant was discarded and the pellet taken up in
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4ml 0.56% potassium chloride solution. After eight minutes of incubation at room
temperature, which leads to the destruction of the cells and nuclei, the solution was
centrifuged under the same conditions and taken up in 2ml fixative (methanol to
glacial acetic acid in a ratio 1:3). This was incubated for five minutes before cen-
trifugation and fixation were repeated twice. Finally, the chromosomes were taken
up in 0.5ml fixative and dripped dropwise onto a glass slide from one meter height.
Slides were stained for ten minutes with 200 µl DAPI before they were washed in
water and embedded in Mowiol. Microscopic pictures were taken under 1,000 x
magnification and chromosomes were counted.
3.3.4 Isolation of Primary Cortical Neurons
Neuronal cultures were isolated as described in El-Tahir et al. [2009]. A E14.5 days
pregnant mouse was euthanised and the uterus removed. Embryos were dissected
and the heads cut off. Using fine forceps, the skull was opened and the brain taken
out with a spoon-like instrument. Under a binocular microscope cerebral cortices
were isolated and the meninges removed with forceps. The cortices were placed in
50ml ice-cold PBS and allowed to settle down. Then these were incubated for ten
to twelve minutes in a shaking 37 ◦C waterbath with 1 ml 0.5% trypsin-EDTA (see
table 2.4) per brain.
A mixture of trypsin inhibitor and 100 mg/ml BSA in H2O (7.5ml trypsin inhibitor
+ 2.5ml BSA) was used to inhibit trypsin. The mixture was allowed to settle for a
few minutes at room temperature, it was then homogenised with a 10 ml pipette in
complete NBMmedium (1ml per brain, see table 2.4). Cells were counted and plated
on poly-l-lysine-coated glass cover slips with 40,000 cells per cm2 and incubated for
48 hours at 37 ◦C, 5% CO2.
3.4 Analysis of Mice
Mice were kept under standard housing conditions in a 12 hour light-dark cycle with
food and water ad libitum. All experiments were carried out in accordance with local
and state regulations concerning animal research.
DNA from mouse tail clippings (see 3.1.3) was used for the genotyping of mice via
PCR.
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3.4.1 PCR for Mouse Genotyping
Table 3.2 – PCR for mice genotyping
(a) Reaction Mix
Amount Components
2 µl Primer 1181 (5 pmol)
2 µl Primer 1482 (5 pmol)
2 µl Primer 1588 (5 pmol)
2 µl Primer SF18 (5 pmol)
50 ng DNA
ad 10 µl H2O
10 µl Redtaq ReadyMix
(b) PCR Program
Step Temp. Time
1 95 ◦C 180 sec
2 95 ◦C 30 sec
3 58 ◦C 45 sec
4 72 ◦C 60 sec to step 2, 34 cycles
5 72 ◦C 300 sec
6 4 ◦C ∞
3.4.2 Southern Blotting Using Church Buffer
Southern blotting allows the detection of a DNA sequence within complete genomic
DNA. Therefore, DNA is restriction digested, separated via agarose gel electrophore-
sis, and blotted on a membrane. Radioactive probes are hybridised with the mem-
brane and can be made visible with a X-ray film.
20 µg DNA from mouse tail clippings were digested overnight using 3 µl EcoRI in a
total volume of 60 µl. On the next morning, 0.5 µl were added and again incubated
for two hours at 37 ◦C. The DNA was then separated on a 0.8% agarose gel without
ethidiumbromide at 60V. A control gel containing ethidiumbromide was run with
1/10th of the digested DNA to control successful digestion.
When the DNA was sufficiently separated, as was evaluated by the running distance
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of bromophenol blue, electrophoresis was stopped. The gel was placed in acidic
depurination (see table 2.6) solution. Incubation was performed two times for seven
minutes under slight shaking. After rinsing the gel in ddH2O for a minute, it was
placed in denaturation solution three times for ten minutes each. For equilibration,
the gel was then placed in 0.4 N NaOH (transfer buffer) for five minutes, afterwards
the Southern blot was assembled as shown in figure 3.1. A vessel containing transfer
buffer was bridged with a plastic tray, on which a piece of Whatman paper con-
nected both sides of the transfer buffer. The agarose gel was then placed upside
down on the Whatman paper, with the Hybond XL membrane on top. Three layers
of Whatman paper with the same size as the gel were placed on top. An about
15 cm pile of paper towel was stacked, finished with a weight of 250 - 500 g on top.
Blotting was performed overnight.
Figure 3.1 – Assembly of a capillary blot. This picture illustrates the assembly of a
capillary blot. Image modified from "‘Nucleinsäure-Blotting"’, Darling, D.C., Brickell, P.M.,
Spektrum, Akad. Verlag, 1996, Page 67.
On the next day, the blot was disassembled. The pockets of the agarose gel were
marked on the membrane using a needle. Then the membrane was equilibrated ten
minutes in 1 x NaPi (table 2.6) and subsequently left to dry for 30 minutes at room
temperature on a piece of Whatman paper. To fix the DNA on the membrane, it
was then baked for two hours at 80 ◦C.
The membrane was prehybridised for two hours at 65 ◦C in Church hybridisation
solution (table 2.6).
The radioactive probe was prepared by digesting plasmid no. 610 with the FastDi-
gest enzymes XhoI and XbaI. After gelextraction and quantification, 50 ng of DNA
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were labelled using the Stratagene Primer it II labelling kit according to the manu-
facturer’s instructions.
Illustra MicroSpin G-50 Columns (GE Healthcare) were used to purify the probe
from unincorporated nucleotides according to the manufacturer’s instructions. 15 µl
radioactive probe were denatured, adding 15 µl 2 M NaOH and incubated for ten
minutes. Afterwards, the radioactive probe was added to the prehybridised mem-
brane and hybridised overnight at 65 ◦C.
The membrane was placed in a plastic container and rinsed two times in prewarmed
65 ◦C Church washing buffer. The buffer was discarded and fresh washing buffer
was added. The plastic container was then placed in a shaking water bath at 65 ◦C.
Every five to ten minutes, the radioactivity of the membrane was measured using a
handheld Geiger counter. This was performed until radioactivity reached approxi-
mately 0.5 to 1Bq/cm2. Afterwards, the membrane was sealed into a plastic bag.
Autoradiography was performed using an intensifying screen (Kodak).
3.4.3 RT-PCR
Total RNA from mice was prepared as described in 3.1.6. 0.5 µg RNA was reverse-
transcribed using the Qiagen QuantiTect kit according to the manufacturer’s in-
structions. 1 µl of the mix was used to perform a PCR.
Table 3.3 – Reverse Transcription PCR
(a) Reaction Mix
Amount Components
2 µl Primer (5 pmol)
2 µl Primer (5 pmol)
1 µl cDNA
ad 10 µl H2O
10 µl Redtaq ReadyMix
(b) PCR Program
Step Temp. Time
1 95 ◦C 180 sec
2 95 ◦C 30 sec
3 56 ◦C 30 sec
4 72 ◦C 60 sec to step 2, 34 cycles
5 72 ◦C 300 sec
6 4 ◦C ∞
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3.5 Protein Biochemistry
3.5.1 Preparation of Protein Lysates
Either primary tissues or cells were used to produce homogenates for the detection of
proteins via Western blotting. Cells were washed with 37 ◦C prewarmed PBS once.
They were then scraped from the surface of the plate with a cell scraper in 1ml of
PBS. The suspension was transferred to a 1.5ml reaction tube and centrifuged for
five minutes at 500 x g. The supernatant was discarded and the cell pellet was lysed
using protein lysis buffer (see table 2.6). For this, 250 µl lysis buffer were added
to the pellet and the mixture was suspended. This was then incubated on ice for
30 minutes. The homogenate was then sonificated three times for 15 seconds each.
Between the sonification steps the samples were incubated on ice for 30 seconds.
The samples were then centrifuged for 30 minutes at 18,000 x g and 4 ◦C, to separate
insoluble cell parts. The protein-containing supernatant was then transferred to a
fresh reaction tube and used for protein estimation. Lysates were stored at -20 ◦C.
To generate lysates from mouse tissue, immediately after preparation, the tissues
were shock frozen in liquid nitrogen and stored at -80 ◦C until further processing.
Tissues were weighted and 500 to 1000 µl per 100mg lysis buffer was used for ho-
mogenisation. The frozen tissue was transferred to a glass-Teflon homogeniser, the
lysis buffer was added and the tissue was homogenised on ice. Homogenates were
then incubated on ice for 20 minutes and further treatment took place as described
above for cell lysates.
3.5.2 Protein Estimation
For the estimation of protein amounts in cell and tissue homogenates, the BioRad
DC Protein Assay was used (principle see Lowry et al. [1951]) according to the
manufacturer’s instructions. A BSA concentration series ranging from 0.0625mg/ml
to 2mg/ml BSA in PBS or lysis buffer was used to determine the concentration of the
sample. The extinction was measured at 750 nm using a Tekan microplate reader.
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3.5.3 SDS-PAGE
For immunoblot detection, protein lysates were separated on a sodium dodecyl sul-
fate polyacrylamide gel electrophoresis (SDS-Page), blotted on a membrane and
incubated with specific antibodies. Detection took place with enhanced chemilumi-
nescence.
If not stated otherwise, 12.5% SDS- PAGE gels were used in this thesis, since they
allow optimal separation of proteins between 12 and 60 kDa.
See table 3.4 for the composition of a 12.5% SDS-PAGE gel. Gels with a thickness
of either 0.75mm or 1mm were used.
For sample preparation 4 x Laemmli buffer was added to 50 µg protein in the ap-
propriate amount to dilute to 1 x buffer. The samples were then placed in a heating
block for five minutes at 95 ◦C. After cooling down on ice, samples were applied to
the gel. 100V were applied to the gel until the samples reached the separating gel.
Then the potential was raised to 200V until the bromophenol blue in the loading
buffer ran out of the gel.
Table 3.4 – Components of a SDS-PAGE gel
Components 1ml Stacking gel (5%) 5ml Separating gel (12.5%)
Water 604 µl 2,100 µl
40% Acrylamid 125 µl 1,560 µl
Tris HCl(*) 250 µl 1,250 µl
10% SDS 10 µl 50 µl
10% APS 10 µl 50 µl
Temed 1 µl 5 µl
(*)Tris HCl pH 6.8 for stacking gel and pH 8.8 for separation gel.
3.5.4 Western Blotting (Semi-Dry)
Western blotting is a technique that allows the transfer of proteins from an SDS-
PAGE gel to a membrane in order to allow detection of specific proteins with anti-
bodies. In this thesis nitrocellulose membranes were used.
When the SDS-PAGE was finished, the gel was subsequently placed in blotting
buffer (see table 2.6) while the blot was set up. Whatman paper and nitrocellu-
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lose membrane were cut to the size of the gel and pre soaked in blotting buffer.
From anode to cathode, three layers of Whatman paper were stacked up, followed
by the membrane, the gel, and another three layers of Whatman paper. The setup
was checked to be free of bubbles, before blotting was performed for 45 minutes at
3mA/cm2.
After successful blotting, the membrane was blocked in 5% skim milk/TBS for one
hour at room temperature. All incubations were performed on a shaker. Incubation
with the first antibody (see table 2.12 for dilutions) was performed for one hour at
room temperature, or overnight at 4 ◦C in 0.5% skim milk/TBS-T. The membrane
was subsequently washed with TBS-T three times, for five minutes each. Incubation
with the secondary antibody was performed for one hour at room temperature in
0.5% skim milk/TBS-T. Again the blot was washed three times with TBS-T, fol-
lowed by a last five minute washing step in TBS. The Pierce ECL western blotting
substrate was used for the detection of the peroxidase-coupled secondary antibody,
according to the manufacturer’s instructions.
The Odyssey infrared imager allows the detection of two proteins at the same time
using secondary antibodies coupled to fluorophores. The protocol is performed as for
the enhanced chemiluminescence method, but no substrate is required. Membranes
are scanned wet using the Odyssey imager.
3.6 Histology
3.6.1 Immunocytochemistry (ICC)
Immunocytochemistry (ICC) allows the visual detection of proteins inside the cell.
Cells were cultured on glass cover slips in 24-well plates under normal culturing
conditions. For fixing, they were washed once with PBS. Subsequently, 500 µl 4%
PFA were added and incubated for ten minutes at room temperature. The PFA
was discarded and the cover slips were washed with PBS two times. Cells were per-
meabilised using 0.2% triton-x-100/PBS for seven minutes. Following this, cover
slips were placed upside down on a piece of Parafilm, on which 30 µl blocking solu-
tion ( 3% bovine serum albumin (BSA) in PBS) have been dripped. For primary
antibody incubation, the antibody (see table 2.12 for instructions) was diluted in
1% BSA/PBS and incubated for one hour as described above. Cover slips were
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then washed three times by slewing them in PBS, before placing them on a drop
containing the secondary antibody in 1% BSA/PBS. Again the cover slips were
washed, adding a final washing step in water, drying them on tissue paper, before
embedding them in Mowiol on a glass slide. After drying for 24 hours, the slides
were microscopically analysed.
3.6.2 Immunohistochemistry (IHC)
Immunohistochemistry (IHC) enables the visual detection of specific proteins in tis-
sues with antibodies. Paraformaldehyde (PFA)-fixed tissue is embedded in paraffin
and cut with a microtome.
Tissue Preparation and Paraffin Embedding
For tissue preparation, mice were euthanised with chloroform and the tissues of
interest were removed. They were placed in 4% PFA for fixing for 12-24 hours
at room temperature. After washing in PBS for three times to remove the PFA,
the tissues were dehydrated using the Tissue-Tek VIP machine. It performed the
following dehydration series: 2 x 70% ethanol, 2 x 96% ethanol, 3 x 100% ethanol,
2 x xylene; each step taking one hour. This was followed by four paraffin steps, 45
minutes each.
When the dehydration was complete, the tissues were embedded in paraffin using
metallic forms. Forms were kept cool for 30 minutes at -8 ◦C on a cooling plate,
before the paraffin block was taken out and stored at 4 ◦C until sectioning.
Paraffin Sectioning
Paraffin blocks were pre-cooled to -8 ◦C on a cooling plate before they were sectioned
using an RM 2155 microtome (Leica). Usually 4 µm thin sections were cut, these
were transferred with a brush to a 42 ◦C water bath. The sections were placed
on a SuperFrost plus microscope slide, which are positively charged and thus allow
better adherence of the tissue. The sections were kept overnight in a 37 ◦C incubator,
which allows vaporisation of residual water, and were then stored at 4 ◦C for further
processing.
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Staining of Paraffin Sections
Deparaffinisation was the first step in staining of paraffin sections. Glass slides were
placed in a rack and washed using the following series: 2 x ten minutes xylene,
2 x ten minutes 100% ethanol, 2 x five minute 96% ethanol, 1 x five minutes 70%
ethanol, 1 x 50% ethanol, tap water. Slides were then stored in tap water until
antigen retrieval was performed. Antigen retrieval was undertaken in a microwave
vacuum histoprocessor RHS-1 for 20 minutes at 95 ◦C. The type of antigen retrieval
is depended on the antibody, see table 2.12 for details. Slides were placed in a
beaker glass and completely covered in the buffer of choice (e.g. 2 mM EDTA pH 8
for HRP-3 staining).
Antigen retrieval was followed by cooling down the slides to room temperature by
applying water from the outside of the beaker glass for 30 minutes.
Slides were washed in TBS once, before permeabilising for seven minutes in 0.2%
Triton-X-100/TBS, followed by three more washes in TBS. Glass slides were placed
in a wet chamber and blocked with 30-150 µl 3% BSA/TBS for one hour at room
temperature. The first antibody was diluted in 1% BSA/TBS and incubated overnight
at 4 ◦C. Glass slides were washed three times in TBS. Following this, they were in-
cubated for one hour at room temperature in a solution of fluorescent secondary
antibody and DAPI diluted in 1% BSA/TBS. Slides were embedded in Mowiol and
left to dry for 24 hours and stored at room temperature.
Chromogenic Immunohistochemistry
For chromogenic staining, sections were treated as described in 3.6.2. After anti-
gen retrieval, slides were washed three times in TBS. To block endogenous per-
oxidases, the sections were incubated for ten minutes in 3% H2O2 in H2O. Slides
were again washed three times in TBS, then they were permeabilised for seven min-
utes in 0.2% Triton-X-100/TBS, followed by three more washes in TBS. Sections
were blocked and incubated with the primary antibody as described above. For the
HRP-3 staining, a biotinylated goat anti rabbit secondary antibody, diluted 1:200
in 1% BSA/TBS, was used. Incubation took place for one hour at room tempera-
ture. Then, the solutions from the Vectastain ABC kit were prepared according to
the manufacturer’s instructions, given dropwise onto the sections and incubated for
one hour at room temperature. Slides were again washed for three times in TBS,
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before development took place. A 0.05% solution of 3,3’-Diaminobenzidine tetrahy-
drochloride (DAB) with 0.03% H2O2, was given onto the sections until a satisfying
signal was reached. Sections were subsequently washed in water and dehydrated for
embedding in the following way: 1 x 30 seconds in 70% ethanol, 2 x 30 seconds in
96% ethanol, 2 x 30 seconds 100% ethanol and 1 x 30 sec xylene. Slides were then
embedded in DPX mounting medium.
For immunohistochemistry of GFP, slides were treated as described above, up to
the incubation with the primary antibody. The mouse anti GFP antibody (Roche)
was diluted 1:500 in 3% BSA/TBS and incubated overnight at 4 ◦C on the slides.
Slides were washed for three times in TBS, then the Super Sensitive link-label-IHC
detection system (BioGenex) was used. This system uses the biotin-streptavidin
amplified (B-SA) instead of the avidin-biotin complex (ABC) method. Instead of
20 minutes, as described by the manufacturer, the solutions were incubated for one
hour each. The slides were washed three times for five minutes in TBS, between
and after the incubation with link and label solution. Development was performed
with DAB as described above, but a longer time (up to ten minutes) was needed to
gain signals.
3.6.3 Whole Mount Staining
Whole mount embryo staining was performed using a slightly modified protocol, de-
rived from www.abcam.com/technical. An E11.5 pregnant mouse was euthanised,
cut open and embryos were transferred into ice-cold PBS. All extraembryonic tissues
were carefully removed and the embryo was fixed in 4% PFA overnight at 4 ◦C.
On the next day, embryos were transferred to a 12-well plate. Three washes with
1% Triton-X-100/PBS, 30 minutes each, were performed. Embryos were blocked
twice for one hour at room temperature in 1ml 5% normal goat serum (NGS) +
1% bovine serum albumine (BSA) in PBS. To inhibit endogenous peroxidases, em-
bryos were placed in block solution with 0.1% H2O2 overnight at 4 ◦C.
The next day, embryos were washed twice for ten minutes in block solution and then
placed in block solution containing c-terminal HRP-3 antibody (1:100), as well as
0.1% sodium azide. Incubation took place for four days at 4 ◦C.
Embryos were washed three times, one hour each, in 1%Triton/block solution and
then three times, ten minutes each, in 1%Triton/PBS to remove traces of sodium
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azide. The secondary antibody, diluted in blocking buffer (goat anti rabbit biotiny-
lated, 1:200), was added and the embryos incubated for two days at 4 ◦C.
On the following day, embryos were washed three times for ten minutes each in
1%Triton/PBS. For three hours, they were incubated in Vectastain ABC-Kit which
was prepared according to the manufacturer’s instructions. For development, em-
bryos were placed in a 0.05% solution of 3,3’-Diaminobenzidine tetrahydrochloride
(DAB) with 0.03% H2O2. When the staining showed the desired intensity, embryos
were washed in PBS and pictures were taken with a binocular microscope.
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4 Results
4.1 Organisation of the Targeting Vector
The HRP-3 targeting construct is composed of two homologous regions, a 1.4 kb
short arm and a 10.6 kb long arm. These regions are necessary for the homologous
recombination event. The short arm allows PCR-based screening from the genomic
area to the inserted targeting vector. A longer homologous region is more efficient
for a successful homologous recombination event. A loxP-flanked reporter gene
and a positive selection cassette are located between those homologous arms. As a
reporter gene, eGFP without a promoter is employed. It uses the endogenous Hrp-3
promoter and therefore allows visualisation of HRP-3 expression.
The hypoxanthine phosphoribosyltransferase (HPRT) minigene is used for positive
selection. It is an enzyme of the salvage pathway, which adds ribose-5-phosphate
to hypoxanthine and thus produces inosine monophosphate, an intermediate in the
purine metabolism. HM-1 cells are HPRT-deficient (Magin et al. [1992]). Medium
that contains hypoxanthine, aminopterin and thymidine (HAT-medium) is used as
a selection medium. Aminopterin inhibits DNA de novo synthesis, thus forcing the
cell into the salvage pathway for DNA synthesis. Only those cells that successfully
took up the HRPT gene are able to survive in selection medium.
Additionally, a negative selection is included in the targeting vector. A diphtheria
toxin fragment A (DT-A) cassette is localised upstream of the short homologous arm.
In case of a random integration of the whole targeting vector, DT-A expression will
kill the cells. A DT-A cassette enables a tenfold reduction in the amount of false-
negative clones (Yagi et al. [1990]). To prevent cell death by transient transfection,
no polyA signal was included downstream of the DT-A cassette.
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4.1.1 Construction of the Targeting Vector
The targeting vector is a modified version of the plasmid Exon2KO-HSV, which did
not succeed in the production of targeted ES cell clones. It was cloned by Rainer
Gallitzendoerfer. In short, Exon2KO-HSV is a GFP-knockin vector that targets
exon 2 of Hrp-3. The HPRT minigene and the GFP are flanked by two loxP sites
and two homologous regions, one short 5’ arm (1488 bp) and a long 3’ arm (4999 bp).
A thymidine kinase cassette is located antisense to the long arm. The performed
modification includes three parts. The 5’ arm is shortened to allow an efficient PCR-
based screening. A longer 3’ arm is cloned to enhance the change of a homologue
recombination event. Lastly, a diphteria toxin cassette (DTA) as a negative selection
is inserted on the site of the short homologous arm.
PvuI, ClaI,
ends filled up with T4 
polymerase,
PspOMI
Ecl136II, PspOMI
Exon2KO-HSV (5196 bp)
Amp DTA
PmeI
5' arm eGFP HPRT
loxP loxP
pDTA (3972 bp)
Figure 4.1 – First step of the cloning strategy for HRP-3-Exon2KO6.1. The plasmid
Exon2KO-HSV was cut using PvuI and ClaI. The generated ends were blunted with T4
polymerase, then the fragment was cut with PspOMI. Subcloning into the Ecl136II/PspOMI
cut pDTA vector led to the product pDTA-Exon2KO.
The first part of the cloning strategy is detailed in figure 4.1. Exon2KO-HSV was cut
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using the restriction enzymes PvuI and ClaI. ClaI was necessary to cut a fragment
with a similar size as the target fragment. This digestion resulted in the following
products: 15,244 bp, 6946 bp, 5085 bp, 1993 bp, 1044 bp and 176 bp.
The 6946 bp fragment was gel-extracted and then blunted using T4 polymerase to
fill up the PvuI-generated sticky ends. Subsequently, the fragment was cut using
PspOMI, resulting in the main 5196 bp and a smaller 1752 fragment. The big-
ger fragment was gel-extracted and subcloned into pDTA. The target vector pDTA
had been cut with Ecl136II/PspOMI. The resulting 3972 bp fragment was then sep-
arated from the 129 bp fragment by gel extraction. This resulted in a plasmid,
pDTA/Exon2KO, which was control digested using PvuII. This led to the expected
products of 6655 bp and 2513 bp.
Amp
pBSK (2957 bp)
BamHI BamHISmaI
EcoRI
BclI BclI
Exon III
Exon IV
Exon V
BclI
PCR Product (10617 bp)
BamHI
Product 1 Product 2
Figure 4.2 – Second step of the cloning strategy for HRP-3-Exon2KO6.1 The PCR
product, generated with primers SF04 and SF05 was cut with BclI and subcloned into the
BamHI-cut, dephosphorylated pBSK backbone. The two possible products were identified via
EcoRI control digestion.
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pDTA-Exon2KO (6655 bp)
NotI,
blunted
13 kb pbSK (13578 bp)
PvuII
Exon IIIExon V
Exon IV
Amp 3' homologous arm
PmeI PspOMI
DT-A 5' homologous arm eGFP HPRT
Product 1 HRP-3Exon2KO6.1
Figure 4.3 – Third step of the cloning strategy for HRP-3-Exon2KO6.1 pDTA-
Exon2KO was cut with the blunt end cutter PvuII and the 6655bp fragment gel isolated. The
target vector for subcloning, 13kb-pBSK was cut with the single cutter NotI, subsequently
blunted, dephosphorylated and ligated with the insert. Two plasmids could have possibly
been generated, they were identified with a SmaI control digestion.
Step two of the cloning strategy is pictured in figure 4.2. To clone the long homolo-
gous arm, the BAC clone bMQ440-k24 (Source BioScience, UK) was used as a PCR
template. A 12,976 bp fragment, containing the region upstream of exon 2, was am-
plified using the primers SF04 and SF05. The PCR product was digested with BclI,
which cut two times, generating three fragments: 10,617 bp, 1707 bp and 652 bp.
The 10,617 bp fragment was gel-purified and subcloned into the BamHI site of the
2957 bp pBluescript II SK(-) vector (Stratagene). Since the insert can integrate in
two directions, the two possible products had to be differentiated by a control di-
gestion. A digest with EcoRI led to the following three fragments for the plasmid
with the false integration: 11097 bp, 1612 bp and 865 bp. For the correct integration
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(which was named 13kb-pBSK) the three resulting fragments were 8176 bp, 3784 bp
and 1612 bp.
Step three is described in illustration 4.3. 13kb-pBSK was cut with the single cut-
ter NotI and subsequently treated with T4 Polymerase to achieve blunt ends. The
13574 bp fragment was gel-extracted.
pDTA/Exon2KO was digested with PvuII, leading to fragments sized 6655 bp and
2513 bp. The bigger fragment was ligated with the NotI-cut, blunted 13kb-pBSK
fragment. Thus producing the final targeting vector, HRP-3-Exon2-KO6.1. To
screen for correct insertions, the plasmid was cut with SmaI. The wrong product
results in fragments of 13267 bp, 3792 bp and 3174 bp. The correct plasmid leads to
sizes 10884 bp, 5558 bp and 3792 bp. The result of the control digestion with SmaI is
shown in figure 4.4. DNA from 15 colonies was analysed, six of them were positive for
the correct integration (number 1, 2, 4, 5, 13, 14 and 15). The other colonies showed
a restriction pattern resulting from either wrong insertion or the original plasmids,
pDTA-Exon2KO (3792 bp and 5372 bp) or 13kb-pbSK (13,578 bp). A midi scaled
DNA preparation was performed for colonies number 4 and 15 and further restric-
tion digested were performed. Colony number 4 was sent for partial sequencing to
GATC Biotech (Konstanz, Germany) and used for all further experiments. The
sequencing results as well as a complete plasmid map can be found in the supple-
ment. For the targeting experiments, HRP-3-Exon2KO6.1 was digested with PmeI
for linearisation.
4.2 Gene Targeting in Embryonic Stem Cells
4.2.1 Targeting Scheme
Illustration 4.5 pictures the homologous recombination of the targeting vector with
the wild type allele resulting in the mutant allele. The Hrp-3 gene consists of six
exons, with a 30 kb gap between exon 1 and exon 2. Previous experiments targeting
exon 1 were not successful. Therefore the construct that is used here, targets exon
2, thus creating a fusion protein of exon 1 and eGFP.
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Figure 4.4 – Control digested DNA from mini preparations. For the last cloning step,
15 colonies were analysed by DNA preparation and subsequent DNA restriction digestion with
SmaI and agarose gel electrophoresis. Undigested controls for colonies 1, 6 and 15 were used
as negative controls as well as the original plasmids used for the ligation (pDTA-Exon2KO
and 13kb-pbsk). Colonies number 1, 2, 4, 5, 13, 14 and 15 show a restriction pattern fitting
to the expected 10884 bp, 5558 bp and 3792 bp. Other colonies show an integration into the
wrong direction (8 and 9) or the pattern of the origin plasmids (3, 6, 7, 9, 11 and 12).
Wildtype allele
Targeting vector
Mutant allele
I II III IV VIV
GFP HPRTDTA
loxP loxP
III IV VIV
ecoRI
ecoRIecoRI
GFP HPRT
loxP loxP
ecoRIecoRI
SF18 1588
1181
1482
probe
probe
5687 bp
3834 bp
SA
Figure 4.5 – Targeting scheme for Hrp-3 exon 2. The wild type allele of Hrp-3 consists
of six exons (depicted as narrow black boxes, named I-VI), exon 2 is targeted with this plas-
mid. The homologous regions are marked by crossed lines. GFP is the reporter gene, HPRT
the selection cassette. DTA the negative selection cassette, that is not included if a homol-
ogous recombination occurs only in case of a complete and random integration. Arrowheads
designate genotyping primers. The southern blot probe, as well as the restriction enzyme
cutting sites (EcoRI) and the resulting fragments are depicted as well. SA marks the splice
acceptor side from exon 2. The mutant allele shows the successfully integrated reporter gene
and selection cassette.
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4.2.2 Targeting of Embryonic Stem cells
In the successful targeting experiment, 14 96-well plates were populated with ES cell
clones. All plates were subcultured on four plates, from which two were for freezing
and two for DNA extraction. Via PCR and Southern blot analysis, it was screened
for clones with a successful homologous recombination of the targeting vector. Only
one positive ES cell clone was detected, number 9.45, the 45th clone of the 9th 96-well
plate.
Picture 4.6 shows the section of the Southern blot that includes clone #9.45. The
5687 bp-sized wild type band can be seen in most of the clones. If there is no
band visible, the cell clone did not grow successfully or there was not enough DNA
isolated. Only for clone number 45, a part of a second band is visible which fits the
size of the expected 3834 bp knockout fragment.
Figure 4.6 – Southern blot screening of embryonic stem cell clones Screening of
embryonic stem cells was performed for each 96-well plate. The part of the autoradiograph
containing clone #9.45 is pictured here. The wild type band at 5687 bp is visible in most of
the clones. Only in clone #9.45 an additional band at 3834 bp is visible (framed).
Image 4.7 shows a photo of the agarose gel electrophoresis of the PCR corresponding
to the first part of plate number 9. In some clones are background bands or genomic
DNA visible, since the amount of template DNA was not quantified. Only for clone
#9.45 a single clear band at the expected size of 2,368 bp is visible.
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Figure 4.7 – PCR-based screening of embryonic stem cell clones #9.01 to #9.72
The electrophoresis of the ES cell genotyping PCR shows a clear band at 2,368 bp for clone
#9.45.
4.3 Generation of HRP-3-deficient Mice
Clone #9.45 was expanded and its correct karyotype confirmed by karyotype analy-
sis. Then, it was used for morula injection in C57Bl/6N morulae. The injection was
performed by the Haus für experimentelle Therapie (HET) in Bonn. It resulted in
the birth of two highly chimeric offspring, from which one was female and one male
(see picture 4.8).
The mice were mated to C57Bl/6N wild type mice and resulting offspring was anal-
ysed for its coat colour. Brown-coloured offspring indicated successful germline
competence. Black-coloured offspring originated from the C56Bl/6N morula.
While the female mouse gave birth to two brown mice, none of them heterozygous,
the male fathered less then 50% brown-coloured offspring, from which half were
heterozygous and thus founded the HRP-3-deficient mouse line.
Heterozygous animals that were derived from matings of the male chimerae with
C57Bl/6 females, were backcrossed with C56Bl/6 mice to breed onto a pure genetic
background. Since backcrossing takes between five and 10 generations, analyses
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Figure 4.8 –Chimeric mouse resulting from the
injection of clone #9.45. This picture shows the
male chimera that resulted from the morula injection.
When mated to C57Bl/6N mice, about 50% of the
litter was brown, indicating successful germline com-
petence.
described here were carried out on a mixed background.
4.4 HRP-3-Deficient Mice are Viable and
Reproductive
Litters, arisen from the breeding of heterozygous females with heterozygous males,
were genotyped and showed the expected Mendelian ratio of 50% heterozygous,
25% wild type and 25% knockout animals.
Homozygous knockout mice showed no conspicuous defects or deficits compared to
wild types. They were viable and reproductive. The amount of litters, as well as the
number of babies in the litter was comparable to wild type mice. Although some
HRP-3-deficient females neglected their offspring and showed less parental care, it
was not observed as a permanent condition in the breed.
Up to the age of ten months, no obvious phenotype differing from wild types was
observed. It is likely that homozygous mutant mice have a normal life span, equiv-
alent to their genetic background.
A trend was observed that knockouts were treated more aggressively by their litter
mates resulting in fights and severe bites. No further fighting was seen when the
knockout was removed from the cage. This trend was neither statistically analysed
nor were behavioural tests performed.
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4.5 HRP-3-Deficient Mice Have a White Coat
Colour
HPR-3 knockout mice had mostly a white coat colour. In matings of non-white het-
erozygous animals, 18 of the 21 born homozygous offspring were white. Of the three
non-white knockout mice, two were black and one grey, all of them fathered white
as well as non-white knockout mice. No white heterozygous or wild type animal was
ever born.
Figure 4.9 – Different coat colours in litters of
the HRP-3 mouse line. This picture shows a lit-
ter derived from heterozygous parents. The white
coloured mouse with red eyes is HRP-3-deficient,
whereas all other coat colours indicate either an het-
erozygous or wild type genotype.
Image 4.9 shows a photo of a litter derived from a heterozygous mating. Mice
with a variety of other coat colours were born. This included black, agouti, beige,
bright grey and dark grey, showing no connection between coat colour and genotype.
Only bright white animals with red eyes were shown to be HRP-3-deficient. Due to
possible HRP-3-unrelated phenotypes, non-white animals were preferred for further
matings.
4.6 Proof of HRP-3-Deficiency
HRP-3 expression in wild type, heterozygous and mutant mice was analysed via
Western blotting at the protein level and reverse Transcription (RT)-PCR at the
RNA level. HRP-3-deficient mice express an enhanced form of the green fluorescent
protein (eGFP) instead of HRP-3 under the endogenous promoter. When regarding
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the literature for HRP-3, the main expression is supposed to be in the brain, so this
tissue was chosen for first analyses.
4.6.1 Western Blot Analysis of HRP-3, eGFP and HDGF
Western blot analysis was performed to substantiate that homozygous mice were
completely deficient of HRP-3. For this, 50 µg of brain lysate of wild type, heterozy-
gous and knockout mouse brain were loaded onto an SDS-gel. After separation, the
gel was blotted on a nitrocellulose membrane and processed as described in 3.5.3.
One part of the gel was incubated with anti-C-terminal HRP-3 antibody, one with
an anti-eGFP antibody (ab6556) and one part with an antibody against HDGF as
a loading control.
Figure 4.10 –Western blot analysis of brain lysates. Lysates of wild type, heterozygous
and knockout brains were analysed regarding their HRP-3, eGFP and HDGF expression. The
HRP-3 antibody detected a protein at about 30 kDa which corresponds to HRP-3. A reduced
signal is detected in heterozygous mice and no signal in HRP-3 deficient mice. The GFP
antibody detected a background protein band in all three genotypes at about 28 kDa and a
specific protein slightly higher, which fits to the expected 31 kDa HRP-3-eGFP-fusion protein.
This protein is only detected in the heterozygous and knockout brain. The HDGF antibody
detected two proteins at 38 and 42 kDa, as expected, with no variation to the genotype.
Picture 4.10 shows the result of the Western blot. The HRP-3 antibody detects a
protein with a size of about 30 kDa is detected. HRP-3 has a size of 23 kDa, but,
due to running anomalies, runs at about 30 kDa in an SDS-gel. The signal is weaker
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in the lysate of heterozygous mouse and no signal is detected in the brain lysate of
the deficient animal.
Using the GFP antibody ab6556 from Abcam, a protein of about 28 kDa is visible
in all lysates. Even though this antibody is affinity-purified, it shows several back-
ground bands depending on the type of tissue. Is also recognises a specific protein,
which is only detected in heterozygous and knockout tissue with a size of about
30 kDa. Since the first exon of HRP-3 is still expressed, a fusion protein with a size
of 31Da is expected in mutant tissues.
The HDGF antibody detects two proteins with an apparent molecular weight of
38 kDa and 42 kDa, which do not vary in their intensity depending on the genotype.
4.6.2 Reverse Transcription PCR on Different Tissues
To evaluate whether the HRP-3-deficiency is complete, at RNA level as well as
protein level, total RNA was isolated as described in 3.1.6. The following tissues
were used: the brain, liver, heart and lungs, each from wild type, heterozygous
and knockout animals. After reverse transcribing the RNA to cDNA, a PCR with
cDNA-specific primers was performed. Wild type brain RNA was treated the same
way without the reverse transcriptase, as a control for genomic DNA (-RT).
Eukaryotic elongation factor 2 (EEF2) specific primers were used to amplify an in-
ternal control gene as a reference. A product of 275 bp was expected to be amplified.
As can be seen in figure 4.11, in the top panel, strong signals corresponding to the
correct size were detected by agarose gel electrophoresis in all samples. The inten-
sity of the signals are the same for every sample. Primers 2857 and 2858 were used
to amplify an HRP-3 specific product of 161 bp. As evidenced in the second part
of 4.11, a strong signal is detected in the brain of wild type and heterozygous mice,
but not in the deficient. A very weak signal can be seen in the liver, but slightly
stronger signals in heart and lungs of wild type and heterozygous mice. No signal
is visible in the control without reverse transcriptase.
GFP-specific primers SF194 and SF195 amplify a 231 bp sized fragment. No signal
can be seen in either the brain, liver, heart or lungs of wild type mice. Whereas a
PCR product migrating at the correct size is visible in tissues of heterozygous and
knockout mice. Due to different exposure times, the intensities are not comparable.
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Figure 4.11 – Reverse Transcription PCR on cDNA derived from the brain, liver,
heart and lungs. To analyse the HRP-3-deficiency at the RNA level, total RNA was isolated
from the brain, liver, heart and lungs. After transcription in cDNA, a PCR with gene-specific
primers was performed. The products were separated via agarose gel electrophoresis. PCR
products of the expected sizes, 275 bp for EEF2, 161 bp for HRP-3 and 231 bp for GFP, are
visible. M stands for marker, -RT designates the control without reverse transcriptase.
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4.6.3 Immunohistochemistry of the Brain
Expression of HRP-3
Paraffin sections of adult HRP-3 wild type and mutant brain were stained for HRP-3
for further affirmation. As Heba El-Tahir described in her doctoral thesis (Eltahir
[2009]), HRP-3 is expressed strongly in several regions of the brain. HRP-3-deficient
tissue will allow a confirmation of the specificity of the staining. Four different
regions of the brain were analysed: the olfactory bulb (figure 4.12), the cortex
(figure 4.13), the hippocampus (figure 4.14) and the cerebellum (figure 4.15).
Figure 4.12 – Immunohistochemistry of the olfactory bulb. Paraffin sections of wild
type (+/+) and knockout (-/-) olfactory bulbs were stained using the antibodies rabbit anti
HRP-3 (A and E, red in merged pictures) and mouse anti GFAP (B and F, green in merged
pictures). Nuclei were stained with DAPI (C, G, K, blue in merged pictures). Goat anti rabbit
C3 and alexa 488 goat anti mouse, respectively, were used as secondary antibodies. For the
secondary antibody control, paraffin sections were not incubated with a primary antibody (I
and J). The scale bar designates 100µm.
Figure 4.12 shows 4 µm thick paraffin sections that were stained for HRP-3 and
glial fibrillary acidic protein (GFAP), an intermediate filament protein, expressed
in astrocytes, whose up- or downregulation is a marker for neurodegeneration or
astrogliosis. A nuclear staining can be detected with the HRP-3 antibody in wild
type olfactory bulbs (A), but not in knockout (E) or in the secondary antibody
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control (I), where only a diffuse background is visible. From the inside to the
outside, expression of HRP-3 can be matched to granular cells of the olfactory bulb,
the mitral cell layer that surrounds them, and cells within the glomerular layer.
GFAP staining of wild type and knockout tissue did not show any differences (B,
F).
Figure 4.13 – Immunohistochemistry of the cerebral cortex. The cerebral cortex
above the hippocampus of wild type and knockout mice was analysed for HRP-3 expression via
immunohistochemistry. A GFAP co-staining was performed to check for astrogliosis. Images
A and E show the signal detected with rabbit anti HRP-3 antibody and goat anti rabbit
C3 secondary antibody. The secondary antibody control was performed without a primary
antibody (I and J). Images B and F show the signal that was detected with goat anti mouse
GFAP and alexa 488 goat anti mouse secondary antibody. Nuclei were stained with DAPI (C,
G and K) and D, H and L show the merged results with HRP-3 in red, GFAP in green and
DAPI in blue. The scale bar designates 50µm.
Paraffin sections of the brain, more specifically the cerebral cortex, stained against
HRP-3 and GFAP, are shown in figure 4.13. The antibody against HRP-3 detects
nuclear signals in the cerebral cortex of wild type mice (A), but neither in knockout
mice (E) nor in the secondary antibody control (I). As described in El-Tahir et al.
[2006], the nuclear signal is found in to cells in layer II and III of the cerebral cortex.
No abnormal GFAP staining is detectable in knockout cortices.
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Figure 4.14 – Immunohistochemistry of the hippocampus Wild type and knockout
brains were stained using an HRP-3 antibody and the hippocampi were analysed. Images A
and D show the HRP-3 staining for wild type and knockout, image G the corresponding sec-
ondary antibody control without primary antibody and goat anti C3 as a secondary antibody.
Nuclei are stained with DAPI (pictures B, E and H) and merged images with HRP-3 signals
in red are presented in C, F and I. The scale bar designates 50 µm.
An HRP-3 antibody has been used to detect HRP-3 expression in the hippocam-
pus. Picture 4.14 shows a dominant nuclear HRP-3 signal in the granule cells of the
dentate gyrus of wild type brain. No signals were detectable in the knockout brain
or the secondary antibody control.
Paraffin sections of wild type and knockout brain, more specifically the cerebellum,
were stained with an HRP-3 and β-III-tubulin antibody, depicted in 4.15. HRP-
3 staining in wild type cerebellum shows a strong nuclear signal in the Purkinje
cells (cell bodies and neurites are positive for β-III-tubulin). Scattered cells in the
molecular layer of the cerebellum also show a strong signal for HRP-3. Surprisingly,
there is a weak but consistent expression of HRP-3 in granule cells of the nuclear
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Figure 4.15 – Immunohistochemistry of the cerebellum. Goat anti rabbit HRP-3 and
goat anti mouse β-III-tubulin antibodies were used to detect expression in the cerebellum of
wild type and knockout mice. Goat anti rabbit C3 and alexa 488 goat anti mouse were used
as secondary antibodies. Images A and E show HRP-3 expression in wild type and knockout
cerebellum, images B and F show β-III-tubulin expression. Nuclei are stained with DAPI (C,
G, K) and D, H and L show the merged images with HRP-3 in red and β-III-tubulin in green.
The scale bar designates 50 µm.
layer. According to El-Tahir et al. [2006], granule cells of the cerebellum - in contrast
to granule cells of the hippocampus and olfactory bulb - are negative for HRP-3.
No signal is detectable in in granule cells of knockout mice nor in the secondary
antibody control.
β-III-tubulin staining of the cerebellum does not reveal any anomalies in knockout
mice. The appearance of Purkinje does not differ from wild type Purkinje cells.
Lesion in the Cerebral Cortex
Due to time constraints, only a limited supply of animals older than six months
was available for the analyses that were performed here. In one individual case, a
six-month-old knockout and a respective wild type mouse were analysed via immuno-
histochemistry and cortical lesions were detected in the knockout animal. Figure
4.16 shows paraffin sections of the cerebral cortex of wild type (A and B) and knock-
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out animals (C and D) in different magnifications. The cortex is visibly thinner in
HRP-3-deficient animals than in the wild type control and a loss of the distinctive
lamination is detectable. Furthermore, a major proliferation of microvessels within
the lesions is visible.
Figure 4.16 – Lesions in the cerebral cortex Paraffin sections of brains from wild type and
knockout mice were stained for HRP-3 and nuclei counterstained with hematoxylin. Images A
and B show the cerebal cortices of wild type mice in different magnifications, images C and D
the cortices of knockout mice. The cortex of HRP-3-deficient brains is visibly thinner, cortical
laminas are indistinct and a higher amount of microvessels is visible. Data produced by Prof.
Hartmann, Institut für Anatomie, Bonn
Paraffin sections of the same area were stained for GFAP. Images of this staining
are depicted in figure 4.17. Activated astrocytes indicating an astrogliosis were
4 Results 75
detectable in the knockout but not in the wild type brain.
Figure 4.17 –GFAP staining of the lesion in a cerebral cortex. Paraffin sections of wild
type and knockout mouse brains were stained for GFAP (green). Nuclei were counterstained
with DAPI (blue). Image A depicts the staining in the cerebral cortex of a wild type mouse,
image B in the knockout mouse. Activated astrocytes are clearly visible in B.
Expression of eGFP in Knockout Mice
To confirm the expression of the eGFP reporter gene in HRP-3 deficient tissue,
paraffin sections of the brain were stained against eGFP. Surprisingly, although
multiple GFP antibodies and antigen retrievals were tested, expression of GFP was
only marginally detectable. The only partially successful method used a mouse anti
GFP antibody from Roche, after antigene retrieval with 10mM sodium citrate with
prolonged incubation with the BioGenex supersensitive link-label IHC kit. This led
to very weak but detectable signals. As positive control, paraffin sections of the brain
of 8-days-old pax-2-deficient mice (kindly provided by Sabine Topka, Institut für
Anatomie, Bonn) were used, which expressed GFP under the pax-2 promoter. While
the development of pax-2-sections with 3,3’-Diaminobenzidine tetrahydrochloride
hydrate (DAB) was stopped after two minutes, the development of HRP-3-sections
was stopped after fifteen minutes as no further enhancement of the signal took place.
This included negative controls.
Brightfield pictures of wild type and knockout brain were taken at the same time
to ensure equal exposure and image processing (see picture 4.18, A). Contrast and
brightness were enhanced using GNU Image Manipulation Program (GIMP). The
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Figure 4.18 – Immunohistochemistry of the brain. Immunohistochemistry was per-
formed on paraffin sections of wild type and knockout brains. A mouse anti GFP primary
antibody was detected with the BioGenex Super Sensitive Link-Label kit and the reaction was
developed with DAB for fifteen minutes. Pictures of wild type and knockout brain (A) and
secondary antibody control and knock out brain (B) were taken together to ensure identical
exposure time and image processing. Contrast and brightness were optimised using the GIMP
software.
secondary antibody control and the knockout brain were photographed together as
well (4.18, B). The wild type brain, as well as the secondary antibody control, do
show a weak background staining, with many structures of the brain being clearly
visible (e.g. the hippocampus, the cerebellum). In total, the knockout brain sections
have a darker colour and more specific signals. Some structures of the brain, such
as the olfactory bulb and the cerebellum, show a darker staining than the rest of
the brain. This does fit to HRP-3 expression data in the olfactory bulb and the
cerebellum.
Image 4.20 shows an overview of the complete sections and detailed photos of the
cerebellum and the olfactory bulb of wild type and knockout mice in different mag-
nifications. It is obvious that the entirety of the brain is stained much darker than
the wild type control or the secondary antibody control. But when analysed micro-
scopically, almost no clearly positive structures or single cells can be seen. Single
cells are only stained weakly and a co-staining with hematoxylin makes it impossi-
ble to detect the brown signal. No stained neurites were found. The wild type and
the secondary antibody control show a weak background staining of Purkinje cells
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Figure 4.19 – Immunohistochemistry of the cerebellum of pax-2 mice. Paraffin
sections of brains from pax-2 mice were stained together with HRP-3-deficient mice as a
positive control. After 2 minutes of incubation with DAB substrate, a strong dark brown
staining was visible. Sections were counterstained with hematoxylin for a better structural
overview. The scale bar depicts 100 µm.
in the cerebellum (best visible in magnifications B and F). No staining of granule
cells can be detected in these negative controls, but granule cells are positive for
eGFP expression in knockout brain (D1 and D2). Also, in the olfactory bulb of wild
type mice and the secondary antibody control, background staining can be detected
(magnifications A and E). But eGFP staining of the knockout olfactory bulb shows a
signal that fits to the HRP-3 staining in wild type (see image 4.12, A). The granular
cells, the mitral cell layer and cells in the glomerular layer are stained darker than
the respective controls.
Overall, the signal is very weak and seems to be diffuse. Magnifications of the cor-
tex and the hippocampus are not shown due to the bad signal-to-noise ratio in the
magnifications.
On the other hand, the GFP positive control (picture 4.19) shows a strong dark
brown signal in the developing P8 cerebellum which relates to pax-2 positive in-
terneurons. The GFP staining protocol can therefore be declared as successful.
However, the question, why GFP expression in HRP-3-deficient mice is so weak,
remains.
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Figure 4.20 – Immunohistochemistry of the brain An overview over the complete brains
of wild type and heterozygous mice, as well as the secondary antibody control, stained against
GFP, are shown here. Different magnifications of the olfactory bulb (A1, C1 and E1 are 200
times magnified, A2, C2 and E2 are 400 times magnified) and the cerebellum (B1, D1 and F1
are 200 times magnified, B2, D2, and F2 are 400 times magnified) are depicted on the right.
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4.7 Verification of the Reporter Gene
4.7.1 Native eGFP Fluorescence
Since immunohistochemistry of eGFP was not satisfying, the native eGFP expres-
sion was analysed in collaboration with Prof. Wolfgang Voos of the Institut für
Biochemie und Molekularbiologie. A Fujifilm FLA-5100 fluorescent image analyser
was used to verify reporter gene expression. Therefore, a wild type and a heterozy-
gous mouse, each two-weeks-old, were euthanised and the brains isolated quickly.
They were placed in ice-cold PBS and directly scanned on the fluorescence scanner
from above and below. Then, the hemispheres were cut to attain a sagittal scan.
An excitation at 495 nm and an emission at 519 nm was used together with the filter
LPB.
Figure 4.21 – eGFP-fluorescence of an HRP-3 heterozygous brain. An HRP-3 wild
type and heterozygous brain from two-weeks-old mice were scanned using the Fujifilm FLA-
5100 fluorescence imager. (A) shows the brains from above and (B) from below. Afterwards,
they were cut for a sagittal scan, shown in (C).
Picture 4.21 shows the result of the fluorescent imager. In (A), the brains are scanned
from above. The heterozygous brain shows a clear fluorescence signal, whereas the
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wild type brain is only visible through background fluorescence. The olfactory bulb
shows a stronger signal than the rest of the brain. (B) shows the brains scanned from
the bottom. The same pattern is visible here, only background for the wild type
brain, but a visible fluorescence for the heterozygous brain. In (C), the hemispheres
were cut apart to get a sagittal view into the brain. The cerebellum is clearly visible
showing a signal in the grey matter, whereas the white matter remains dark. The
olfactory bulb again shows a stronger signal than the rest of the brain.
Figure 4.22 – Whole mount HRP-3-staining of wild type embryos E11.5 Wild type
embryos were fixed with PFA, and stained uncut against HRP-3. The secondary antibody
control on the right shows a minimal background staining, whereas in the HRP-3 stained
embryo, many structures are clearly positive. Among them, the developing olfactory pit
(compare pictures B1 and B2), extremities and the somites (compare pictures A1 and A2).
Other features, e.g. the developing heart, show a weaker signal.
4.8 Expression during Embryonic Development
A whole mount staining of E.11.5 wild type embryos was performed to analyse the
HRP-3 expression during embryonic development. The procedure is described in
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3.6.3. Pictures were taken with a binocular and are shown in 4.22. The HRP-3-
stained embryo is depicted on the left, the secondary antibody control on the right.
Many features are clearly stained for HRP-3. The nasal placode, more specifically
the developing olfactory pit, depicted in B1, shows a clear, dark staining at the rim.
The developing extremities, e.g. the forelimb bud and the hindlimb bud, as well as
the branchial archs (1 and 2) show a strong signal. In the enlargement A1, staining
of the somites is visibly stronger than the background of the secondary antibody
control. The developing heart (ventriculus cordis) is slightly stained.
EGFP expression of heterozygous embryos was analysed with a GFP binocular in
cooperation with Dr. Bernhard Fuss from the Department of Molecular Develop-
mental Biology. Some features of the embryo are prominently positive for eGFP, as
for example the extremities and the ear placode. Less structures can be identified
as in the whole mount staining.
Figure 4.23 – Native eGFP fluorescence of HRP-3 heterozygous embryos. E10.5
embryos were extracted and placed on ice-cold PBS for the analysis with a fluorescent binoc-
ular. Picture A shows an heterozygous and a wild type embryo. Picture B the heterozygous
embryo from a different angle.
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4.9 HRP-3 Expression in Other Tissues than the
Brain
4.9.1 Western Blot Analysis of Different Tissues
Reverse transcription of wild type RNA showed weak signals for different tissues
than the brain, namely, liver, heart and lung (see image 4.11). Also, HRP-3 ex-
pression during embryonic development gave signals other than those present in the
brain (see image 4.22). Furthermore, it has been shown that HRP-3 is expressed
in granule cells of the cerebellum, which has been confirmed by a deficiency of that
staining in knockout cerebellum. Western blot analysis of all major organs of an
adult mouse was thus performed to check for expression in a wide variety of tissues.
Figure 4.24 – Western blot analysis of HRP-3 in tissues of an adult wild type
mouse. A six-month-old wild type mouse was dissected, its organs shock frosted in liquid
nitrogen, and prepared for Western blot analysis. 100 µg of protein were loaded onto an
SDS-gel, separated and blotted onto nitrocellulose membrane. The membrane was incubated
with rabbit anti HRP-3 as a primary antibody and peroxidase coupled goat anti rabbit as a
secondary antibody. Mouse anti α-tubulin was used as a loading control.
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The western blot analysis depicted in figure 4.24 presents the expression of HRP-3
in tissues of a six-month-old male C57Bl/6N mouse. By far the strongest signal at
the size of about 30 kDa can be seen in the brain. Due to running anomalies, HRP-3
has an apparent molecular weight of about 30 kDa in SDS-Page. The second highest
expression level can be observed in testis. Medium expression levels can be detected
in spleen, lung and the heart. Weak signals can be detected in thymus and liver.
Surprisingly, HRP-3 is expressed in the glandular part of the stomach, but not in
the non glandular part, or in other parts of the digestive system. Furthermore, the
kidney is the only tissue in which a clear signal at 34 kDa is visible. α-tubulin was
used as an internal marker on the same gel, showing that every sample contained
protein. The tubulin signal in the liver is quite weak, an higher amount of protein
might have led an higher HRP-3 expression level.
Due to the expression data that were shown in Western blot analysis, selected or-
gans were also analysed via immunohistochemistry to confirm these results and to
analyse the expression on the cellular level. The heart, kidney and stomach were
chosen for that analysis and results are presented in the following section.
4.9.2 The Heart
Image 4.25 shows 4 µm thick paraffin sections of the heart of wild type and knockout
mice. Wild type sections were also used as a secondary antibody control. Images
A, D and G show the signals arising from the primary rabbit anti HRP-3 antibody
that was detected with a secondary goat anti rabbit C3 antibody. In images B, E
and H the nuclei are stained with DAPI. Merged images are depicted in C, F and I.
A signal for HRP-3 that colocalises with DAPI can be detected in wild type hearts
(A), but not in knockout (D) or the secondary antibody control (G). The nuclear
signal can be accounted to the nuclei of the heart muscle cells. Cross striations of
the muscle cells are clearly visible.
A diffuse background autofluorescence is observed in knockout and secondary an-
tibody control. Furthermore, fluorescent erythrocytes can be seen in wild type,
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knockout and antibody control.
Figure 4.25 – Immunohistochemistry of the heart Paraffin sections of hearts from wild
type and knockout mice were sectioned and stained using the rabbit anti HRP-3 antibody.
Fluorescent goat anti rabbit C3 was used as a secondary antibody. Secondary antibody control
was not incubated with a primary antibody. Nuclei were counterstained with DAPI. The scale
bar designates 50µm.
4.9.3 The Kidney
Image 4.26 depicts the immunohistological staining of paraffin sections of the kidney
from wild type and knockout mice. Wild type kidney was also used as a secondary
antibody control. The primary rabbit anti HRP-3 antibody was detected with a
biotinylated goat anti rabbit secondary antibody. Development of the chromogenic
signal was performed as described in 3.6.2 with the Vectastain ABC kit. Different
magnifications, 200 times and 400 times, are shown. Nuclei were stained with hema-
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toxilin and show a clear blue colour.
The glomeruli, round structures with cells inside, were photographed in all images.
They perform the first filtering step from blood to urine in the kidney. In wild type
kidneys, these glomeruli contain nuclei that are positive for HRP-3 (images A and
D), most likely the podocytes. The same nuclei do not show a signal in knockout
sections or in the secondary antibody control. Structures around the glomeruli, the
renale tubules, show a strong brown background staining in wild type, knockout and
secondary antibody control.
Figure 4.26 – Immunohistochemistry of the kidney Paraffin sections of wild type (A
and D) and knockout (B and E) kidney were stained with a rabbit anti HRP-3 antibody.
The primary antibody was detected with a biotinylated secondary, followed detection with
the ABC kit from Vectastain as described in section 3.6.2. Sections from images C and F
were not incubated with a primary antibody. Nuclei in all sections were counterstained with
hematoxilin. The scale bars mark 50µm.
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4.9.4 The Stomach
An unusual observation was made in the stomach of HRP-3-deficient mice. A hy-
perplasia of the stomach’s mucosa and submucosa led to the development of strong
foldings in the non-glandular part of the stomach. No other pathological abnormal-
ities were detected. Occurrence of these foldings was not age related.
Figure 4.27 – Hyperplasia of stomach foldings. Images of wild type (A and C) and
knockout (B and D) mice stomachs were taken. A and B are from unperfused six-month-old
animals, while C and D were taken from nine-month-old animals after intracardial perfusion
with 4% PFA. Arrows mark the unusual foldings that can be seen from the outside. Images
C and D were taken by Prof. Hartmann, Institut für Anatomie, Bonn
Figures 4.27 and 4.28 show examples of these stomach foldings. Photos in figure
4.27, A and C were taken of stomachs of wild type mice, B and D of the correspond-
ing knockouts. Arrows mark the areas where the horizontal foldings can be seen
clearly. Figure 4.28 shows stomachs from four other mice, cut open and emptied.
While the inside of wild type mice stomachs is relatively smooth, distinct foldings
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and more tissue can be detected in the respective knockouts.
Figure 4.28 – Hyperplasia of stomach foldings. Images of wild type (A and C) and
knockout (B and D) mice stomachs were taken. Stomachs were dissected from nine-month-old
mice, cut open and their contents flushed out. Foldings are marked with arrows. Images were
taken by Prof. Hartmann, Institut für Anatomie, Bonn.
Figure 4.29 shows a histological staining of stomachs of wild type and HRP-3-
deficient mice. HRP-3 expression in the stomach of the wild type mouse is clearly
nuclear in several types of cells, which can be attributed to parietal cells, chief cells
and cells located beneath the mucous neck cells. Additionally, parietal cells show
a weak cytosolic signal (4.29, A). No clear staining is detectable in the knockout
(B) nor in the secondary antibody control (C). An abnormal cellular distribution
was detected in a stomach of another HRP-3-deficient mouse (D). Parietal cells are
localised in the fundus of the stomach, where normally chief cells are located.
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Figure 4.29 – Immunohistochemistry of the glandular stomach. Paraffin sections of
the stomach of wild type and HRP-3-deficient mice were stained against HRP-3. The staining
was detected with a biotinylated secondary antibody, followed by development with the ABC
kit from Vectastain. Image A shows the glandular stomach of a wild type mouse, images B and
D were taken of the stomachs of deficient animals. In image C, no abnormalities regarding the
cellular distribution can be detected. In image D on the other hand, parietal cells are visible
at the stomach fundus, where normally chief cells are located. Image C shows the secondary
antibody control. Nuclei of all sections were counterstained with hematoxylin. The scale bar
designated 50 µm. Image D taken by Prof. Hartmann, Institut für Anatomie, Bonn
4.10 Neuronal Cultures
Abouzied et al. [2010] reported that primary cultures of cortical neurons reacted to
knockdown of HRP-3 via siRNA with shortened neurite length.
To evaluate whether neurons from HRP-3 knockout mice show shortened neurites,
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primary cultures from wild type and deficient E14.5 were isolated as described in
3.3.4. Cells were seeded on poly-l-lysine-coated glass coverslips in 24-well plates
with a concentration of 80,000 cells per well. The cells were cultivated for exactly
24 hours before they were fixed with 4% PFA and stained against beta-III-tubulin
as described in chapter 3.6.1.
Figure 4.30 – Neurite length of wild type and knockout primary cortical neurons
Primary cortical neurons were cultivated for 24 hours and the length of the longest neurite
was determined using the software ImageJ with the plugin NeuronJ. N = 135 wild type cells
and n= 163 knockout cells were blindly analysed. Mean neurite length for knockout cells was
31.79 µm and 31.24µm for wild type cells.
Coverslips were evaluated randomised single-blinded. Five photos of each coverslip
were taken with the Axiovert 100M in areas with 5-15 neurons per visual field. Neu-
rite lengths and the amount of neurites were determined with the software ImageJ
(Meijering et al. [2004]). For each analysed neuron, the longest neurite was measured
to determine the neurite length and the amount of neurites were counted. N=135
knockout cells and n=163 wild type cells were analysed. The result is depicted in
diagram 4.30. The neurite lengths varied strongly, since the cultures were very diver-
sified. But the mean length was 31.79 µm for the knockout cells and 31.24 µm for the
wild type cells. Standard deviation for knockout cells was 17.73 µm and 14.04 µm,
therefore there is no difference in the neurite length of wild type and HRP-3 deficient
primary cortical neurons.
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5 Discussion
The hepatoma-derived growth factor-related protein-3 (HDGFRP-3 or HRP-3) is a
secreted growth factor and a member of the HDGF protein family. In contrast to
other members of this family, which are expressed in a wide range of different tissues,
HRP-3 is predominantly expressed in the brain and exhibits several characteristics
that suggest a function during embryonic brain development. More specifically, ex-
pression of HRP-3 varies quantitatively during brain development. It is strongly
expressed in the embryonic brain, with elevated levels at the time of birth. In
the postnatal brain, the amount of protein is reduced, whereas in the adult brain
stronger expression levels are again reached (Abouzied et al. [2004]).
Like other members of the HDGF protein family, HRP-3 possesses a bipartite nu-
clear localisation signal, which is accountable for its nuclear expression in postmitotic
neurons of the adult brain. Surprisingly, a solely cytosolic signal for HRP-3 can be
attained via immunochemistry in embryonic brain sections or freshly isolated cortical
neurons. A translocation from the cytosol to the nucleus occurs in the early postna-
tal brain for currently unknown reasons (El-Tahir et al. [2009]). According to Xiao
et al. [2012], a translocation from the nucleus to the cytosol in HRP-3-transfected
cells can be obtained by stimulation with epidermal growth factor (EGF).
Furthermore, HRP-3 possesses neurotrophic abilities on primary cortical neurons
and is able to keep these cells alive when added recombinantly as a sole supplemen-
tal factor to the culture medium. Moreover, primary neurons are able to attach and
present full neurite outgrowth when plated on HRP-3-coated cell culture dishes. In
contrast, neither HDGF itself nor β-galactosidase as a recombinant control protein
exhibited these or similar effects when used as a coating reagent (Abouzied et al.
[2010]).
The described effects are manifested by cells when HRP-3 is provided extracellu-
larly. In contrast, intracellular HRP-3 interacts with the cytoskeleton and influences
neurite outgrowth. It was shown that HRP-3 binds to tubulin and is thus able to
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stabilise microtubules. Additionally, the reduction of HRP-3 in primary neurons
via siRNA led to a significant reduction in neurite length and a reduced number of
neurites per cell (El-Tahir et al. [2009]).
Even though the characteristics described above give a few indications, the specific
function of HRP-3 is currently unknown. These indications, however, may suggest
that a loss-of-function mutation of HRP-3 has a drastic impact on the development
of neuronal cells and the brain in total.
HRP-3 is a neurotrophic factor and in general, neurotrophic factors are survival-
promoting agents for neurons whose imbalance in the brain is observed as part of
neurodegenerative diseases (Peng et al. [2005], Zuccato and Cattaneo [2009]). In
rodent models of neurodegenerative diseases, administration of neurotrophic factors
has been successfully examined as a therapeutic treatment, e.g. NGF for choliner-
gic neurons in Alzheimer’s disease, BDNF for dopaminergic neurons in Parkinson’s
disease (PD), CTNF in motorneuron diseases (Lindsay [1994]).
Fundamental research is needed to reach a deeper understanding of neurotrophic
factors and their potential as therapeutic options. Thus, this dissertation describes
the generation of an HRP-3-deficient mouse model with the objective to further
characterise HRP-3 function. HRP-3 is a relatively unknown neurotrophic factor,
thus, information provided by this mouse model should give new insights. Below, the
generation of the knockout construct and the mouse model itself will be discussed,
followed by a characterisation of the HRP-3-deficient mouse and its phenotype.
5.1 Gene Targeting and Generation of Mice
The genomic information for Hrp-3 is located on mouse chromosome 7 (human chro-
mosome 15). It is composed of six exons, with a 30 kb gap between the first two ex-
ons. This made exon 1 an appealing target for previous gene targeting experiments.
Although different approaches and constructs have been tried, these experiments
were unsuccessful for several years. Therefore, a new construct was to be designed
and cloned that should implement a different targeting approach for the homologous
recombination. The new targeting strategy included several characteristics:
• The construct was planned to be plain and without extensive features. Target-
ing experiments with conditional knockout constructs have been unsuccessful
before, so a traditional knockout was therefore intended.
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• Longer homologous arms increase the probability of a successful targeting ex-
periment (Deng and Capecchi [1992]). Therefore a 10.6 kp long region of ho-
mology was used as 3’ arm for the targeting construct. The other region of
homology is only 1.4 long, to ensure a fast PCR-based screening.
• A Diphteria toxin-A (DT-A) cassette for negative selection gives a tenfold
higher chance of a homologous recombination event (Yagi et al. [1990]).
The successful homologous recombination event is depicted in figure 4.5. The start
codon and exon 1 of the Hrp-3 gene are left intact. Since the splice acceptor site of
exon 2 is integrated in frame with the eGFP reporter gene in the targeting vector,
a fusion protein is expressed. The 31 kDa sized exon-1-eGFP-fusion protein is thus
expressed under the endogenous Hrp-3 promoter.
The hypoxanthine phosphoribosyltransferase (HPRT) minigene was used for pos-
itive selection. Since HM-1 cells are deficient for the HRPT-gene, this allowed a
selection for cell clones with successful integration of the minigene, using medium
supplemented with hypoxanthine, aminopterin and thymidin (HAT-supplement).
The targeting vector was constructed in three steps (see figures 4.1, 4.2 and 4.3): a
DT-A cassette was subcloned into an older version of an exon 2 targeting construct,
generated by Rainer Gallitzendörfer. A PCR-amplified 10.6 kb long homologous
region was then added as a long homologous arm. The resulting plasmid, HRP-
3-Exon2KO6.1 was then control digested (see figure 4.4) and partially sequenced
(sequencing results can be found in the supplementals).
1344 embryonic stem (ES-) cell clones were picked in the targeting experiment that
led to the isolation of positive clone number 9.45. Four copies of all 96-well plates
were produced. The cell clones were genotyped via Southern blot and PCR analysis,
although not all of them were successfully genotyped for different reasons. Not all
cell clones grew confluent enough to isolate DNA for Southern blot analysis. PCR
analysis led to the identification of false positive clones, so that a new genotyping
PCR had to be established during mid-screening. DNA digestion for Southern blot
analysis in 96-well plates had to be modified slightly due to insufficient results. The
targeting experiment was repeated while clone # 9.45 was injected, and led to the
identification of another positive ES-cell clone out of 480 clones in total. In the
meantime, the male chimera, resulting from the injection of clone # 9.45, produced
heterozygous offspring, so the other clone was not used for blastocyst injection.
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The targeting frequency depends on several different factors, e.g. the length of ho-
mologous regions or the use of isogenic DNA. It is also locus dependent (Hasty et al.
[1991], Müller [1999]). Due to the previous negative results, and considering these
facts, the long homologous region was cloned from an isogenic BAC clone. Still, the
targeting frequency for Hrp-3 was extraordinary low with around 1/500 to 1/750.
In contrast, the targeting frequency for HDGF has been 4 positive clones from 144
analysed (Gallitzendoerfer et al. [2008]). However, HRP-3-Exon2KO6.1 was the first
targeting vector to successfully undergo homologous recombination in ES cells and
the positive clone was confirmed via Southern blotting (see figure 4.6) and PCR
genotyping (see figure 4.7).
Morula injection was performed at the Haus für experimentelle Therapie, Bonn.
From the two resulting highly chimeric mice (see photo 4.8), one led to the founding
of the HPR-3-deficient mouse line. As expected, 50% of the resulting offspring with
a brown coat were heterozygous for the inserted mutation, thus successfully giving
rise to the mutant mouse line.
In addition to Southern blot and PCR analysis, the expected deletion of Hrp-3 was
further confirmed in mutant mice at protein level by Western blot analysis (see figure
4.10). The amount of protein was shown to be reduced in heterozygous animals and
no signal was detectable in homozygous animals. The same result was confirmed at
RNA level (see figure 4.11).
5.2 Coat Colour
One of the first observations regarding the HRP-3-deficient mouse line was that mice
homozygous for the mutation were prevalently white and had bright red / pink eyes
(see photo 4.9). No animal that was heterozygous or wild type for the Hrp-3 locus
was ever born with a white coat colour. This indicates that the white coat colour
is recessive and does not originate from the mixed genetic background of the mice
(129ola and C57Bl/6).
A reasonable explanation for the white coat is a genetic linkage of the mutant Hrp-3
locus with a mutation in a locus responsible for coat colour. Two loci or a combi-
nation of both are possible candidates here. The first, tyrosinase (tyr), is a locus
encoding for the key enzyme in the synthesis of the pigment melanin, converting
L-tyrosine to 3,4-dihydroxyphenylalanine-(DOPA-)quinone. Mutations in the tyr
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locus that interrupt the melanin synthesis lead to an absence of the pigment (Saran
et al. [2004]). This would explain the observed coat colour and the non-pigmented
eyes.
The tyrosinase locus is linked with the p locus, this linkage on chromosome 7 is the
first linkage described in literature (Brilliant et al. [1997]). The p locus encodes for
the p protein, also named oca-2 or pink-eyed dilution, because mutations in this
locus lead to oculocutaneous albinism form II in humans. In mice, different spon-
taneously occurring mutations are known that cause hypopigmented eyes and fur,
leading a dilution of the original coat colour (Brilliant [2002]). The p protein is
probably needed for the transport of tyrosinase into melanosomes (Toyofuku et al.
[2002]). P-deficient mice have melanosomes that are smaller than usual and contain
only a little amount of pigment (Brilliant [2002]). Since these animals are still pig-
mented, no bright white-coated mice would result from these mutations, therefore
a linkage to this locus alone would not explain the coat colour.
According to the Mouse Genome Database (MGD, http://www.informatics.jax.org),
Hrp-3 is located on chromosome 7, position 89026137 - 89079359 bp (45.71 cM). The
tyrosinase gene is located on the same chromosome, position 94575915 - 94641921 bp
(49.01 cM) and the p locus on position 63495130 - 63791887 bp (33.44 cM). The ge-
netic distance between Hrp-3and tyr is thus only 3.3 cM. One centimorgan equals
a 1% chance of two genes getting separated during meiosis and does not always
relate to their distance on the chromosome. Since the white coat colour is a re-
cessive phenotype, the number of heterozygous animals with the genetic linkage on
one allele is not known. Theoretically, in a homozygous animal there should be a
6.6% chance (3.3% for each allele) of a separation of the two loci. Since the event
of a double recombination is not distinguishable from no recombination event, the
number might even be lower. In this thesis, 21 homozygous mice originated from
heterozygous matings, a 6.6% chance of separation would result in 1.4 non-white
animals. In reality, 3 of 21 were grey or black, indicating a successful separation of
the loci, which is a higher number than expected.
It is possible that the HM-1 cells themselves already have the mutations on chromo-
some 7 necessary to create the white coat colour heterozygously. In that case, the
mutant chromosome was targeted and the linkage not separated. Another possibil-
ity is that the mutation was acquired in the ES-cells or during the first matings of
the mouse line.
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The same phenomenon of a white fur colour linked to the genotype has been re-
ported for Bax-deficient mice (http://jaxmice.jax.org/faq/bulletin/bulletin02.html,
and Hamann et al. [2009]). Bax is a tumorsupressor, its genetic information is lo-
cated on chromosome 7 at 29.32 cM and is linked to tyr and p. According to the
Jackson Laboratory, it was not possible to separate the loci even after 8 generations
of breeding with C57Bl/6 mice. Furthermore, some mutations in tyr and p are
linked to several defects, for example neurological disorders, decreased viability and
fertility (Brilliant [2002]). This was the reason why non-white homozygous mice
were mated with C57Bl/6 wild type mice or heterozygous animals, leading to white
and non-white offspring. Still, most homozygous mutants analysed in this thesis
were white.
5.3 Expression Analysis of HRP-3
Up to now, HRP-3 protein has only been detected in the brain and testis (Abouzied
et al. [2004]). Northern blotting analysis of human RNA indicated further HRP-3
expressing tissues, as the heart, kidney, lung, liver and pancreas (Ikegame et al.
[1999], Xiao et al. [2012]). As a reason for this unclear expression data, Abouzied
et al. [2004] discussed differences between human and mouse HRP-3 and a protein
level that is too low to detect in Western blotting. An N-terminally histidine-tagged,
shortened form of HRP-3, lacking the first 100 amino acids, was used to immunise
rabbits for antibody production as described in Abouzied et al. [2004]. The rea-
son why a shortened form was used is in the high level of homology in the HATH
(Homologous to the Amino Terminus of HDGF)-domain between the HDGF fam-
ily members, which might lead to a cross reaction of the antibodies with different
family members. The antibodies were then purified from the rabbit antiserum by
immunoaffinity chromatography using glutathione S-transferase (GST)-tagged re-
combinant HRP-3.
For the experiments described in this thesis, new antiserum had to be produced.
This time, a full length N-terminal histidin-tagged form of HRP-3 was used to
immunise rabbits (immunisation by Pineda, Berlin, Germany). After affinity purifi-
cation against GST-tagged HRP-3, the resulting antibody was tested. It was shown
to recognise HDGF as well as HRP-3 in Western blot analyses. Affinity purification
was then performed with the shortened form of HRP-3, lacking the HATH-region,
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so that only antibodies binding to the non-HATH part of HRP-3 would be purified.
The resulting antibody did not show any further cross reaction with HDGF and
gave extraordinarily good signals for HRP-3 in Western blotting and immunocyto-
and immunohistochemistry.
This antibody was used to perform a Western blot analysis on different wild type
mouse tissues to address the question of HRP-3 expression (see figure 4.24). With
this antibody, HRP-3 is detectable not only in the brain, but also several other
tissues. Namely, the thymus, spleen, liver, kidney, heart, lung, and the glandular
part of the stomach; however, not the non-glandular part. These results were also
confirmed in RT-PCR (figure 4.11) where HRP-3-specific primers detected a signal
of the correct size in the liver, heart and lung of wild type and heterozygous, but
not homozygous animals, indicating a specific signal. RT-PCR with eGFP-specific
primers on the other hand did not lead to any signals in wild type tissues, but in
heterozygous and knockout brain, heart, lung and liver, where the expression of the
HRP-3-exon1-eGFP fusion protein under the endogenous HRP-3 promoter indicates
the expression of HRP-3.
This new expression data was supported by immunohistochemistry. Figures 4.12,
4.13, 4.14 and 4.15 present an analysis of several brain regions, where HRP-3 ex-
pression has been reported before (Abouzied et al. [2004]). The signals in wild type
brain are not detectable in knockout tissue or in the secondary antibody control.
The same was shown in other tissues beside the brain, namely, the heart, the kidney
and the stomach (compare figures 4.25, 4.26 and 4.29). HRP-3 expression in these
organs is confined to the nucleus of heart muscle cells, podocytes in the kidney and
parietal cells of the stomach. The relatively small amount of HRP-3 in contrast to
the volume of the whole organ explains the low level of expression and why these
signals have not been detected before. The other organs (the thymus, spleen, liver
and the lung) have not yet been analysed for their subcellular HRP-3 expression.
One additional, as yet unknown, locus of expression of HRP-3 was found in the
granule cells in the cerebellum. This was a surprising result, since no staining in
granule cells has been detected before, not even in low amounts (Abouzied et al.
[2004]). Compared to the Purkinje neurons, the staining of granule cells is somewhat
weaker, but still clearly visible. It resembles the pattern that is shown when brain
sections are stained with an antibody against HDGF (El-Tahir et al. [2006]). But
the affinity purification against the shortened form of HRP-3 without the HATH-
5 Discussion 98
region diminishes the detection of other family members, particularly HDGF. Also,
no signal was retained in HRP-3 knockout cerebellum (figure 4.15, picture E). The
staining was confirmed by using a different antibody against HRP-3 (mouse anti
HRP-3 by Santa Cruz, see table 2.12). This antibody detected the same signal in
granule cells, which was diminished in knockout brain and the secondary antibody
control.
In Western blot analyses of wild type tissues, it was further confirmed that no other
polypeptides were detected except the 30 kDa sized protein that resembles HRP-3
(see figure (4.24). The possibility of a cross reaction of the antibody with other
HDGF family members was thus excluded.
The results presented here show new expression loci for HRP-3 that include not only
further tissues than the brain, but also different cell types within the brain. Since
all expression levels are much lower in all other tissues beside the brain, a possible
explanation is that the antibody has a higher sensitivity and thus already detects
a lesser amount of protein. But this does not explain the staining of granule cells
of the cerebellum in immunohistochemistry. For these cells, at least a low signal
should have been detected in earlier stainings, but this was not the case.
Since a polyclonal antibody is a mixture of antibodies binding to several different
epitopes on the same protein, it is possible that the antibody used here has other
epitopes than the one published in Abouzied et al. [2004]. Immunisation of the rab-
bit was performed with the full length protein, a mixture of recombinant bacterial
and eukaryotic HRP-3 produced in HEK-cells. Since eukaryotic proteins are post-
translationally modified, these modifications might be possible epitopes that are not
recognised by the previous antibody.
It is likely that the full length protein has a different tertiary structure than the
non-HATH region alone. Thakar et al. [2010] showed that the N-terminal part of
HDGF interacts with the C-terminal part. The same might be the case for HRP-
3, thus presenting different regions of the protein for antibody production. These
regions might lead to a higher immunological response. Also, the use of a larger
protein might lead to a higher response of the immune system.
It is possible that the antibody detects postranslational modifications of HRP-3.
But it is also possible that two different isoforms of HRP-3 were detected here. Ac-
cording to the Ensembl database (http://www.ensembl.org), three transcripts for
HRP-3 exist, two of which are transcribed into proteins. The first transcript codes
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for a protein of 202 amino acids and represents the sequence which is commonly
known as HRP-3. The second protein is produced by alternative splicing without
the sixth exon and has a size of 205 amino acids. The small difference between these
two isoforms makes it hard to distinguish them on the protein level.
Figure 4.10 shows an HRP-3 Western blot result where the exposure time was much
shorter as in 4.24. It can be seen here that there is not only one, but two bands for
HRP-3 which are running very close together, indicating only a small difference in
their apparent size. The same phenomenon was shown for HDGF (Abouzied et al.
[2004]).
In contrast to the protein size, the mRNA size of these potential isoforms varies
strongly (5887 bp in contrast to 2865 bp), so a Northern blot analysis would provide
insights into whether different isoforms exist in different organs or even within the
brain. Additionally, in-situ-hybridisation with specific probes against the different
isoforms, would indicate whether the expression in granule cells is derived from a
different HRP-3 isoform.
It can be concluded that HRP-3 is not only expressed in the brain and testis as was
shown by [Abouzied et al., 2004]. In fact, the substantiated expression shown here,
fits with the results of the Northern blot analysis performed on human RNA by
Ikegame et al. [1999] and Xiao et al. [2012]. The restricted expression of HRP-3 in
contrast to the other HDGF family members was always seen as a unique character-
istic for its neuronal function. The data presented here requires that the functional
analysis of HRP-3 is expanded further beyond its function in the nervous system.
Excluding the kidney, all polypeptides detected with the HRP-3 antibody in im-
munoblot analyses 4.24 have the same molecular weight. In the kidney, a signal is
detected, corresponding to an approximate size of 32-34 kDa, 2-4 kDa bigger than
the usual HRP-3 signal. This is only an estimation, since HRP-3 has a size of
23 kDa, but appears at 30 kDa in SDS-Page due to running anomalies (Abouzied
et al. [2004]). If a modification has an influence on these running anomalies, the
kidney variant of HRP-3 might be more than just 2-4 kDa bigger. Posttranslational
modifications of HRP-3 might be a reason for the increased size of the protein in
the kidney.
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5.4 Expression of eGFP and Possible Secretion
Immunohistochemical detection of eGFP is a standard technique and many com-
panies offer specific antibodies. It was thus surprising that even in areas with a
high expression level of HRP-3, as the olfactory bulb or the cerebellum, no optimal
staining was achieved. Different antibodies against eGFP and different methods
of antigen retrieval were tried. With one of the GFP antibodies and a prolonged
incubation time of all reagents, poor signals were finally derived (see figure 4.18).
A positive control (pax-2 knockout/GFP knockin mouse brain sections, kindly pro-
vided by Sabine Topka, Institut für Anatomie, Bonn) was stained together with
HRP-3-deficient sections and showed satisfactory results, indicating that the stain-
ing protocol was not the problem (see image 4.19).
Signals on HRP-3-deficient brain sections were only marginally stronger than back-
ground staining in the wild type brain and the secondary antibody control. But,
cells that were stained visibly (granule cells of the cerebellum and the olfactory
bulb, images 4.20, C2, D2) were specific compared to the HRP-3 staining in wild
type brains (image 4.15, 4.12). No staining of neurites was detected though, which
is not surprising due to the weak signal strength.
A GFP signal was expected to be cytosolic in contrast to wild type HRP-3, since
no nuclear localisation signal is left in the HRP-1-exon1-eGFP fusion protein. It
was not possible to show this, since co-staining with hematoxylin masked the weak
brown GFP-derived staining completely.
Surprisingly, native eGFP fluorescence, as shown with a fluorescent scanner in het-
erozygous brains (image 4.21), was relatively strong. The native fluorescence in
E10.5 embryos (image 4.23) was clearly detectable. Immunohistochemistry with
chromogenic substances is highly sensitive and should lead to an increase of the
signal.
A discrepancy exists in the detection of GFP: it is easily detectable in Western
blot analysis of whole brain lysates (image 4.10, RT-PCR (image 4.11) and with a
fluorescence scanner or binocular (images 4.23 and 4.21), but not in immunohisto-
chemistry. Of course, processing of paraffin sections for staining takes a long time
and GFP is not bound in the cell since it has no intracellular binding partners.
Due to its solubility it might be washed out during processing. It is more probable
though, that GFP is secreted from the cells and then washed out from the tissue
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during the processing steps. Thakar et al. [2010] describe that HDGF is secreted via
a non-classical secretion pathway that is mediated via the N-terminus of the pro-
tein. When they attached the first ten amino acids of HDGF to GFP or SNAP, they
were able to shuffle these out of the cells into the supernatant; the phosphorylation
at serine 165 is a prerequisite for this secretion process. As all family members,
HRP-3 shares the HATH (homologous to the amino terminus of HDGF)-domain
with HDGF. It is thus not unlikely that HRP-3 is secreted via the same mechanism.
Since exon 1 of HRP-3 is still expressed and localised N-terminally of eGFP, the
same secretion mechanism probably takes place. As Thakar et al. [2010] showed,
GFP becomes a secretory protein when fused to the N-Terminus of HDGF. The
N-termini of HDGF and HRP-3 are not identical (HDGF: methionine, serine, argi-
nine, serine, asparagine, arginine, glutamine, lysine, glutamic acid, tyrosine; HRP-3:
methionine, alanine, arginine, proline, arginine, proline, arginine, glutamic acid, ty-
rosine, lysine) but both contain a high amount of basic amino acids. A comparison
of both protein sequences is depicted in figure 5.1.
Figure 5.1 – Alignment of the protein sequence of HDGF and HRP-3. The protein
sequences of HDGF and HRP-3 have been compared using the software CloneManager. Amino
acids 1-100 share a high degree of identity, the so called HATH-domain. The serine/proline
motif at position 165 of HDGF has an equivalent at position 162 at HRP-3.
The high degree of identity in the HATH region is clearly visible. Also, the serine
165 phosphorylation site in HDGF has an equivalent in HRP-3, a serine at posi-
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tion 162 (both marked with red circles in figure 5.1. Both are followed by proline,
which is discussed by Thakar et al. [2010] to undergo a cis/trans transformation
when phosphorylated. It is known that HRP-3 is secreted in primary cortical neu-
rons (Abouzied et al. [2010]). Since eGFP can be secreted by the amino terminus
of HDGF, it is likely that the same is possible with the amino terminus of HRP-
3. Most of the secreted protein would thus be outside of the cells and get washed
out during tissue processing. That would explain the rare and weak signals in
immunohistochemistry in contrast to the strong signals in other detection methods.
Unfortunately, characterisation of the reporter gene activity in HRP-3-deficient mice
on the cellular level is thus not possible by immunohistochemistry. On the other
hand, analysis via in-situ-hybridisation at RNA level should allow confirmation of
the expression of GFP in the correct localisation and could thus give valuable infor-
mation about the secretion mechanism of HRP-3 and HDGF.
5.5 Hyperplasia of Mucosa and Submucosa of the
Stomach
A unexpected observation in HRP-3-deficient mice was a strong folding of the stom-
ach’s mucosa and submucosa, but without any other pathological changes (fig. 4.27,
4.28). Since the breed was still on a mixed genetic background of 129/ola mice and
C57BL/6, weighting of the animals was not performed. However, HRP-3-deficient
animals did not show signs of obesity or undernourishment. HRP-3 is expressed in
the glandular part of the stomach, but not the non-glandular part (see figure 4.24).
On the cellular level, HPR-3 is expressed in the parietal cells of the stomach.
The stomach mucosa is innervated by extrinsic and intrinsic nerves and especially
parietal cells are described to be highly dependent on nervous stimuli (Ekblad et al.
[2000]). The parietal cells are necessary for the production of hydrochloric acid, a
process which is induced by the release of different stimuli. Histamine, gastrin and
acetylcholine operate via endocrine, paracrine and neurocrine pathways on parietal
cells. Several growth factors play a role in the growth and differentiation of the
stomach. For example, gastrin upregulates the epidermal growth factor (EGF), the
transforming growth factor α (TGFα), and the heparin-binding EGF-like growth
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factor (HB-EGF) (Friis-Hansen [2007]). Also, basic fibroblast growth factor, a neu-
rotrophic factor, was shown to be trophic for gastric nerves (Ekblad et al. [2000]).
Another neurotrophic factor, namely BDNF, influences innervation of the stom-
ach and mechanoreceptors there. These receptors, intraganglionic laminar endings
(IGLE) and intramuscular arrays, connect the gastrointestinal muscles with the va-
gus nerve. The vagus nerve is important for the connection of inner organs, such as
the heart or the digestive system, with the central nervous system. In the stomach it
is, amongst others, important for the intake of food and its digestion. BDNF knock-
out mice show a 50% reduction of intraganglionic laminar endings in the stomach of
newborn mice, while myenteric neurons (their target cells) were unaffected. Three
days after birth, the number of IGLEs is back to wild type level (Murphy and Fox
[2010]). This indicates that other trophic factors are able to substitute for the loss
of BDNF.
These results show that neurotrophic factors also act in the stomach, which could be
possible for HRP-3 as well. It is not clear though, whether the enlarged gastric folds
stand in connection with its neurotrophic activity or general growth factor activity.
Ménétrier disease is a rare human disorder that partially resembles the phenotype
seen in HRP-3-deficient animals. A strong hyperplasia of stomach foldings is charac-
teristic for this disease and is also accompanied by a reduction of parietal and chief
cells. As an origin for Ménétrier disease, an increased stimulation of the epidermal
growth factor receptor (EGFR) is being discussed. The stimulation is induced by
a local overproduction of the EGFR ligand TGFα, which is expressed in parietal
and mucous cells (Coffey et al. [2007]). Mice that overexpress TGFα in the stomach
develop a phenotype that resembles Ménétrier disease. But how exactly the disease
develops is not yet known (Takagi and Jhappan [1992]).
Ogawa et al. [2003] show that histamine H2-receptor-deficient mice exhibit the same
phenotype. The histamine H2 receptor is located on parietal cells and when acti-
vated by histamine, stimulates secretion of hydrochloric acid. Mutant mice older
than sixth months develop a phenotype that resembles Ménétrier disease, including
a local overexpression of TGFα.
Whether or not HRP-3 plays a role in the abnormal signalling that leads to Ménétrier
disease, can not be concluded from the data presented here. Further characterisa-
tions of the enlarged stomach foldings are necessary. On a cellular level, the number
of parietal and chief cells have to be estimated, since these are reduced in the hu-
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man disease. Immunohistochemistry and Western blot analysis of TGFα in HRP-3-
deficient stomachs would reveal an upregulation and thus an increased stimulation
of EGFR.
5.6 Neuronal Development and Cortical Lesions
HRP-3-deficient mice developed normally and did not show any deficits. No histo-
logical abnormalities were detected in the brains of deficient two to six-weeks-old
mice compared to wild type mice. Isolated primary cortical neurons of mutant mice
did not show a shortened neurite length compared to wild type neurons (see figure
4.30). It was thus concluded that HRP-3 is replaceable in embryonic brain develop-
ment. Since HRP-3 is highly expressed in the adult mouse brain (Abouzied et al.
[2004]), a function in the aged brain, as well as a function in the response to injuries
is possible. Emphasis was thus put on the analysis of adult mice. The animals ex-
amined in this thesis were between four weeks and six months old because no older
animals were available. However, it should be kept in mind that older animals also
have to be analysed to gain a complete overview of the effect of HRP-3-deficiency
on the brain.
In the brain of a six-month-old mouse, small lesions within the cerebral cortex were
detected. In these lesions, degenerating neurons and a few activated astrocytes were
found. Unfortunately, time did not permit further analysis of aged HRP-3-deficient
animals. Thus, whether or not HRP-3-deficient mice are prone to such lesions or
even neurodegeneration, cannot be concluded yet and will have to be shown in future
experiments. However, a few possible approaches will be discussed in the following.
Examples in the literature show that, ideally, aged animals between one or two
years should be analysed. For example, Capsoni et al. [2000] created a transgenic
mouse model, expressing an antibody against NGF and thus reducing the amount
of NGF by at least 50%. These mice exhibited an age-dependent neurodegenerative
disease comparable to Alzheimer’s disease. Mice at the age of 15-17 months showed
neuronal loss in the cortex, cholinergic deficits, amyloid plaques and neurofibrillary
tangles.
Mice transgenic for a dominant-negative form of mitochondrial aldehyde dehydroge-
nase 2 (ALDH2), an enzyme necessary to detoxify toxic aldehydes, are histologically
inconspicuous and show no behavioural deficits at the age of sixth months or earlier.
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By contrast, mice at the age of 12 and 18 month, show age-dependent neurodegener-
ation and memory loss (Ohsawa et al. [2008]). These publications place an emphasis
on the importance of the analysis of older animals when searching for neurodegen-
eration.
Degeneration of synapses is one of the earliest signs of neurodegeneration, even be-
fore other markers are detectable. Whether the synaptic dysfunction is a reason for
neurodegeneration or a side effect, is not yet known (Perry and O’Connor [2010],
Milnerwood and Raymond [2010]). It would thus be useful to stain HRP-3-deficient
brain sections with antibodies against synaptical markers. Perry and O’Connor
[2010] found that the first synpaptic markers to be reduced are the vesicle-associated
membrane protein-2 (VAMP-2), cysteine string protein (CSP) and synaptophysin.
It would thus be reasonable to analyse HRP-3-deficient brains with these markers.
Furthermore, the demise of synapses is accompanied by a loss of mitochondrial func-
tion but not a reduction in their number. Cytochrome c oxidase activity is reduced
and the mitochondria undergo morphological abnormalities (Perry and O’Connor
[2010]). Mitochondria are also discussed as a cause for the onset of neurodegenera-
tive diseases (Johri and Beal [2012]). Analysis of mitochondrial markers should thus
be performed.
Fluoro-Jade B (Millipore) is described to specifically stain degenerating neurons and
activated astroglia, although the reason for the binding is not known (Schmued and
Hopkins [2000]). Paraffin sections of two five-month-old knockout and respective
wild type brains were stained with Fluoro-Jade B, yielding no differences compared
to wild type sections. This is not surprising, since paraffin sections with a thickness
of 4 µm are too thin to make out small areas of degeneration. To screen for such ar-
eas, a complete brain should be cut into 50 - 100 µm thick sections using a vibratome
and then the sections should be stained with Fluoro-Jade B. Due to the low number
of animals at the right age, this was not possible as part of this thesis.
In later stages of a neurodegenerative disease, cells undergo apoptosis, necrosis
and / or autophagic cell death. Staining with apoptotic marker, e.g. activated
caspase-3, will indicate if apoptosis is taking place in the brain.
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5.7 Comparison with Other Loss-of-Function
Mutations
Loss-of-function mouse models of other neurotrophic factors show strongly varying
phenotypes, depending on which specific factor (or its corresponding receptor) is
deleted. Some show drastic phenotypes, as for example the neurotrophin-3 (NT-3)-
deficient mouse model. Mice have huge deficits in neuronal development of sensory
neurons, which occur before and during target innervation. Homozygous mutants
die within 48 hours after birth (Tessarollo et al. [1994], Ernfors et al. [1995]). Inter-
estingly, trkC-deficient mice (trkC is the main receptor for NT-3) develop normally
until postnatal day two and live about 30 days. This phenotype is a milder version
of the NT-3-deficiency, since NT-3 is still able to use trkA and trkB as receptors
(Tessarollo et al. [1994]).
Conover et al. [1995] created BDNF and neurotrophin-4/5 (NT-4)-deficient mice,
as well as double knockout mice. BDNF-deficient mice show immense neurological
deficits, coordination problems and die usually within three weeks after birth. Mice
that are heterozygous for the deficiency still exhibit aggressiveness between males,
increased eating habits and weight gain. They also show a degeneration of sero-
tonergic neurons, for which BDNF is a trophic factor. Human psychiatric diseases
such as obsessive compulsive disorder (obsession for hand washing etc.), bulimia and
others are also linked with an imbalance of the serotonin level and are treated with
drugs that enhance the serotonin level (Lyons et al. [1999]).
A better comparison for the HRP-3-deficient mouse model are mice with a homozy-
gous deletion for the NT-4 gene. These mice are viable and fertile and show no
obvious neurological deficits up to the age of ten months, which is comparable to
HRP-3-deficiency. Conover et al. [1995] assumed that NT-4/5 activity is important
during responses to injury or aged nervous system. Interestingly, Fox et al. [2001]
show that the amount of vagal sensory neurons is reduced by more than the half
in NT-4-deficient mice, whereas other neuronal cell types are not affected. Defi-
cient mice show a huge decrease (80.9%) of mechanoreceptors in the small intestine.
These receptors (intraganglionic laminar endings and intramuscular arrays) connect
the gastrointestinal muscles with the vagus nerve. In contrast, mechanoreceptors in
the stomach are unchanged compared to the wild type control. As a result, mice
showed a changed eating habit, with a 76% longer duration of meals. Body weight
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and total food intake was not affected due a reduced amount of meals compared
to the wild type control. This is a rather mild phenotype and shows that loss of
neurotrophic factors does not always cause massive deficits, but can also be supple-
mented within the body. Deficits in the number of mechanoreceptors do not inhibit
normal life or changes the behaviour of mice and is therefore a phenotype which
is hard to detect. Also, the HRP-3 mouse model might exhibit such inconspicuous
abnormalities, especially since it is now known that it is expressed not only in the
brain but in a number of different organs. Further, and more detailed analyses are
necessary here.
5.8 Functional Replacement of HRP-3 in
Knockout Mice?
Wat et al. [2010] discuss that human patients with microdeletions on chromosome
15.q25.2, which includes the genomic locus of Hrp-3, are susceptible for congenital
diaphragmic hernia (CDH). The authors hold the loss of HRP-3 responsible for the
cognitive deficits arising in this disease. No hernia was detected in HRP-3-deficient
mice, but conclusions cannot be drawn about cognitive deficits since no behavioural
analyses were performed. Unexpectedly, brain development of HRP-3-deficient mice
is not disturbed. It was presumed that HRP-3 plays a role during brain develop-
ment, for example by establishing neuronal polarity or neurogenesis. A reduction of
HRP-3 via siRNA led to significantly shortened neurites in primary cortical neurons
(El-Tahir et al. [2009]). However, the complete deficiency of HRP-3 shows no effect
in primary cortical neurons that have never produced HRP-3. It is possible that the
function of HRP-3 is replaced by other proteins in vivo.
The same was shown for HDGF itself in deficient mice. No phenotype differing
from wild type mice was detectable. Although an upregulation of other proteins
was discussed by Gallitzendoerfer et al. [2008], none of the other family members
were found to be upregulated. It was assumed that in HRP-3-deficient mice no
upregulation in other family members would happen either. HDGF expression was
therefore analysed via immunoblotting, which confirmed this assumption (compare
figure 4.10). Further analyses of other family members and growth factors still would
have to be performed.
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A substitution of HRP-3 protein function is not restricted to HDGF-family mem-
bers. Since HRP-3 is predominantly expressed in the brain, other neurotrophic fac-
tors could intervene to fulfil the missing function. It would be interesting to analyse
expression patterns of different neurotrophic factors in HRP-3-deficient brains.
According to D. Sanes, A. Thomas [2006] central neurons, in contrast to periph-
eral neurons, have multiple targets and to decrease neuronal survival, two or more
growth factors have to be disrupted. Even though that is not the case for most of
the members of the neurotrophin family, it might be the case for HRP-3 and HDGF.
Many growth factors are needed in emergencies, e.g. in case of injury, as for exam-
ple the platelet-derived growth factor (Werner and Grose [2003]). It is possible that
HRP-3 has a similar function. Eltahir [2009] showed in nerve crush experiments
that HRP-3 is downregulated and translocates into the cytoplasma after nerve in-
jury. The effect of HRP-3 on injury could be analysed in vivo and in vitro. For
example, injury can be induced chemically in cell culture by the activation of the
NMDA or AMPA/kainate receptors (Carriedo et al. [1996]).
If two or more trophic factors share the same receptor, the same signalling cas-
cade can still be induced and the phenotype rescued. For example, the fact that
trkB-deficient mice die within 24-48 hours after birth was not reproduceable in
BDNF/NT-4 double knockouts. TrkB receptor knockout mice have a decrease of
motorneurons in the facial nucleus, a trait which double knockout mice do not ex-
hibit. Therefore, it was correctly assumed that trkB acts as a receptor for another
neurotrophin (compare figure 1.2, Conover et al. [1995]). To date, no receptor for
HRP-3 is known. It can only be speculated whether stronger deficits are rescued in
this mouse model by other growth factors.
5.9 HRP-3-deficient Mouse Model as a Tool for
Further Analyses
The HRP-3-deficient mouse model is a versatile tool and can be used for further
analyses on HRP-3 protein functions.
Since eGFP is probably secreted out of the cells by the use of the first ten amino
acids of HRP-3, this permits study of the secretion mechanism. Using antibodies
against GFP, the exon 1-eGFP fusion protein could be purified from brain lysates.
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With the help of mass spectrometry, interaction partners could be identified and
thus elucidate the secretion mechanism of HDGF and HRP-3. Classical secretion
can be blocked by the inhibitor brefeldin A (Nickel [2010]), which should not in-
fluence secretion of HRP-3 / GFP. Primary neuronal cultures can be a useful cell
culture model here, because it is known that they secrete HRP-3.
Furthermore, the question remains, how HRP-3 is internalised by cells. Primary
neuronal cultures might also be used here. These cultures do not show any dif-
ferences to wild type cultures in growth and neurite lengths. Using recombinant
HRP-3, the cultures can be fed and checked via immunocytochemistry for inter-
nalised HRP-3. The blockage of receptors with different inhibitors then allows an
investigation of possible receptors of HRP-3. On the other hand, an internalisation
via macropinocytosis with the involvement of heparane sulfates and activation of
map kinase downstream signalling was shown for HDGF and the HATH domain
(Wang et al. [2011]). The blockage of macropinocytosis with the inhibitor amiloride
should diminish the uptake of HRP-3, if it happens via this mechanism.
In the same cell culture model, it can be examined whether the neurotrophic and
neurite-outgrowth abilities of extracellular HRP-3 also leads to the intracellular ef-
fects of HRP-3 (stabilisation of microtubules). One possibility for further studies
is the quantitative analysis of acetylated tubulin after cells have been fed with re-
combinant HRP-3. This could be a way to show the direct uptake of HRP-3 and a
subsequent modulation of the cytoskeleton.
The literature discusses that, like HDGF, HRP-3 is a protein overexpressed in tu-
mours. Ortega-Paino et al. [2008] described the overexpression of HRP-3 in mantle
cell lymphoma, Xiao et al. [2012] in hepatocellular carcinomas. Although the re-
duction of HDGF in tumours via siRNA leads to enhanced apoptosis, necrosis and
reduced blood vessel formation (Zhang et al. [2006], Liao et al. [2010]), it is not
classified as an oncogene and is described as a factor for non-oncogene addiction.
Proteins of this category are not oncogenes, but are upregulated in tumours; tumour
growth and progression depends on them (Sedlmaier et al. [2011]). It is likely that
the same concept is valid for HRP-3. In this case, HRP-3 might serve as a prognostic
marker or even as a target in cancer therapy. Further validation is needed here.
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5.10 Outlook
Unfortunately, the mouse model generated did not allow to draw a specific conclu-
sion regarding the function of HRP-3 within the scope of this thesis. However, a
foundation for further analyses of HRP-3 was laid.
Most importantly, the existence of lesions within the cerebral cortex has to be con-
firmed or disproven. Mice should be analysed via vibratome sectioning of the brain
including evaluation of neurodegenerative, apoptotic and inflammatory markers; the
animals should be as old as possible.
In this thesis, the analysis of HRP-3-deficient mice was predominantly focussed on
the brain. The new expression data described here demands further histological
analyses of all new HRP-3 expression loci in wild type mice and a comparison to the
corresponding knockout tissue. The hyperplasia in the stomach of HRP-3-deficient
mice strongly indicates that a phenotype differing from wild type does not have to
be restricted to the brain.
For histological analyses, the likely secretion of eGFP in these mice is unfortunate,
but it might proof useful for an investigation of the non-classical secretion mecha-
nism of HRP-3.
Summary
This dissertation describes the generation of a mutant mouse model and its initial
analysis. The hepatoma-derived growth factor-related protein-3 (HRP-3) is a growth
factor of the HDGF protein family with neurotrophic activity. Predominantly ex-
pressed in the brain, it was shown to bind and stabilise microtubules and a function
during brain development is speculated in the literature.
Although multiple targeting experiments with different vectors were tried, targeting
of the HRP-3 locus has been hitherto unsuccessful. The targeting strategy used in
this thesis was thus modified to target exon 2 with a classic non-conditional knock-
out. Even though the targeting frequency was clearly below average, the mutant
mouse line was finally created.
It was discovered that HRP-3, in contrast to findings in contemporary literature, is
indeed predominantly expressed in the brain, but also to lesser extent in a range
of other tissues and specific cell types. These include podocytes in the kidney or
heart muscle cells. It can thus be supposed that the function of HRP-3 is not only
confined to the brain, but also extends to other organs. Additionally, it was also
shown that expression of HRP-3 within the brain extends to more cell types than
previously reported.
It is highly probable that the reporter gene eGFP is secreted due to a secretion
mechanism supported by the first ten amino acids of HRP-3. To analyse this non-
classical secretion pathway, this might prove useful.
Mice were viable and fertile and lived up to the age of ten months without any
obvious abnormalities. A single case of a six-month-old mouse with small lesions in
the cerebral cortex was found, but due to time constraints and the absence of older
animals, these results were not reproduced.
Furthermore, some HRP-3-deficient animals exhibited a hyperplasia of stomach mu-
cosa and submucosa, resulting in extreme stomach folds. Since it was shown that
HRP-3 is expressed in the parietal cells of the stomach, a phenotype is conceivable.
The mutant mouse model might prove useful as a model for human Ménétrier dis-
ease, but this has to be further researched.
Due to these unanswered questions and the fact that the mouse model at hand war-
rants more a extensive analysis, it might provide interesting possibilities for further
studies of HRP-3.
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6 Supplemental Data
Figure 6.1 – Plasmid map of the targeting vector. A map of the targeting vector,
HRP3-Exon2KO6.1, including selected enzyme cutting sites, is shown here. PmeI was used to
linearise the plasmid before electroporation, EcoRI and SmaI were used for control digestions.
Abbreviations: Amp (ampicillin resistance), 3’ and 5’ (3’ and 5’ homologous arms), loxP (locus
of X over P1, allows site-specific recombination with Cre-recombinase), HPRT (hypoxanthine
phosphoribosyltransferase, positive selection), GFP (enhanced green fluorescent protein), SA
(splice acceptor site of exon 2), DTA (diphteria toxin fragment-A, negative selection cassette),
1482 and 1181 are the primers necessary for the mouse genotyping PCR. 2004, 2742, EGFP-
C2-RP and EGFP-N are primers that were used for partial sequencing of the targeting vector.
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Figure 6.2 – Sequencing result with primer pEGFP-C2-RP. Sequencing with primer
number pEGFP-C2-RP (GATC standardprimer, sequence: GATCACATGGTCCTGCTG)
led to a sequence of the GFP cassette. Sequencing was performed by GATC Biotech, Koblenz.
Figure 6.3 – Sequencing result with primer 2742. Sequencing with primer number 2742
(sequence: CACAGAGGGCCACAATG) led to a sequence of part between the HPRT cassette
and the 3’ homologous arm. Sequencing was performed by GATC Biotech, Koblenz.
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Figure 6.4 – Sequencing result with primer 2004. Sequencing with primer number 2004
(sequence: TCTCCCCTCTCCTTTTCCAT) led to a partial sequence of the 3’ homologous
arm. Sequencing was performed by GATC Biotech, Koblenz.
Figure 6.5 – Sequencing result with primer EGFP-N. Sequencing with primer number
EGFP-N (GATC standardprimer, sequence: CCGTCCAGCTCGACCAG) led to a sequence
of the GFP cassette and the 5’ homologous arm. Sequencing was performed by GATC Biotech,
Koblenz.
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